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Abstract 
Objectives: Medication side effects are common, often leading to reduced quality of life, non-
adherence and financial costs for health services. Many side effects are the result of a 
psychologically-PHGLDWHGµQRFHERHIIHFW¶7KLVUHYLHZLGHQWLILHVWKHULVNIDFWRUVLQYROYHGLQ
the development of nocebo effects. 
Methods: Web of Science, Scopus, Medline, PsychINFO, Journals @ Ovid full text, and 
Global health were searched using WKHWHUPV³QRFHER´DQG³SODFHERHIIHFW´7REHLQFOXGHG
studies must have exposed people to an inert substance and have assessed one or more 
baseline or experimental factor(s) on its ability to predict symptom development in response 
to the inert exposure.  
Results: 89 studies were included, 70 used an experimental design and 19 used a prospective 
design, identifying 14 different categories of risk factor. The strongest predictors of nocebo 
effects were a higher perceived dose of exposure, explicit suggestions that the exposure 
triggers arousal or symptoms, observing people experiencing symptoms from the exposure, 
and higher expectations of symptoms.  
Conclusions: In order to reduce nocebo induced symptoms associated with medication or 
other interventions clinicians could: reduce expectations of symptoms, limit suggestions of 
symptoms, correct unrealistic dose perceptions, and reduce exposure to people experiencing 
side effects. There is some evidence that we should do this especially for persons with at-risk 
personality types, though exactly which personality types these are requires further research. 
These suggestions have a downside in terms of consent and paternalism, but there is scope to 
develop innovative ways to reduce nocebo effects without withholding information. 
Key words: nocebo effect, predictors, symptoms, inert exposure, review 
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Adverse drug reactions (ADRs) are common (Davies et al., 2009), and can have 
serious implications in terms of patient well-being and adherence (Ammassari et al., 2001) as 
well as significant financial costs for health services (Monguio, Otero, & Rovira, 2003; 
NICE, 2009). However, ADRs are not always related to the physiological action of the 
medication (Faasse & Petrie, 2013).  Only 10.9% of reported ADRs to commonly prescribed 
drugs are clearly attributable to the medication (de Frutos Hernansanz et al., 1994). It is 
thought a nocebo effect may play a role in the formation of other apparent side effects 
(Barsky, Saintfort, Rogers, & Borus, 2002). As well as medication side effects, nocebo 
effects have been implicated in symptoms attributed to technological exposures such as 
electro-magnetic fields (EMF) from mobile phones and Wi-Fi (Baliatsas et al., 2012; Rubin, 
Cleare, & Wessely, 2008). A nocebo effect is the experience of negative symptoms following 
exposure to an inert substance, which are triggered or exacerbated by psychological 
mechanisms such as expectations (Kennedy, 1961). 7KHQDPHµQRFHER¶ZDVFUHDWHGWR
distinguish between the desirable µSODFHER¶and undesirable effects of an inert exposure 
(Hauser, Hansen, & Enck, 2012), although in practice the distinction between undesirable and 
desirable is not always clear cut. For example increased alertness maybe beneficial in some 
contexts (e.g. prior to an examination) and detrimental in others (e.g. prior to sleep).   
Current literature suggests there are three main mechanisms for a nocebo effect; 
misattribution, expectation, and learning. Misattribution theory suggests that people 
misattribute pre-existing symptoms to the effects of a new exposure (although some authors 
believe that misattribution does not technically constitute a nocebo effect, see Enck, Bingel, 
Schedlowski & Rief, 2013; Colloca & Miller, 2011). Symptoms are common in everyday life 
(Petrie, Faasse, Critchon, & Grey, 2014), and although often harmless and short-lived, when 
people are subjected to a new exposure, symptoms that were present before or occur 
coincidentally are available to be mistakenly attributed to it (Petrie et al., 2005; Petrie, Moss-
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Morris, Grey, & Shaw, 2004). Therefore factors such as high baseline symptoms or high self-
awareness may serve as risk factors for nocebo effects resulting from this mechanism. 
Negative expectations can also mediate nocebo effects (Hahn, 1997), and may in turn arise 
through explicit suggestions about the effects of an exposure (Jaen & Dalton, 2014; Myers, 
Cairns, & Singer, 1987), or predisposing factors such as pessimism (Geers, Helfer, Kosbab, 
Weiland, & Landry, 2005).  These negative expectations can make the individual more likely 
to attend to new or current sensations, and attribute them to the exposure (Barsky et al., 
2002). The response expectancy theory suggests that it is also possible for negative 
expectations to act more directly, with an expectation of, for example anxiety, being itself 
provoke anxiety thereby directly causing the negative effect that was expected (Kirsch, 
1997a,b). The last mechanism, learning, can elicit nocebo effects through association or 
social observation.  For example, if an inert stimulus has been previously paired with a 
symptom-inducing stimulus (Barsky et al., 2002), which may occur through conscious or 
non-conscious mechanisms (Stewart-Williams, 2004), or through observing someone else 
experience symptoms to the same exposure (Vogtle, Barke, & Kroner-Herwig, 2013). 
Given the significant costs nocebo effects can have on patient quality of life and 
health services it is important to develop interventions to minimise these effects from 
occurring. Many risk factors have been implicated, but no study has systematically reviewed 
these to identify those which are the strongest predictors of nocebo effects; something that 
would assist in the development of such interventions.  Instead, previous systematic reviews 
have focused on the magnitude of nocebo effects for a specific symptom, e.g. Petersen et al. 
(2014) or in clinical trials of experimental medical treatments (Hauser, Bartram, Bartram-
Wunn, & Tolle, 2012). One review (Symon, Williams, Adelasoye, & Cheyne, 2015) has 
provided a preliminary assessment of some of the risk factors involved in nocebo effects. 
+RZHYHUWKLV³VFRSLQJUHYLHZ´LGHQWLILHGRQO\SDSHUV± a limited subset of the available 
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literature. To address this gap our systematic review aimed to identify the risk factors 
involved in the reporting of any symptom in response to an inert exposure. This will allow 
the identification of factors which appear to be consistent predictors of nocebo effects and aid 
in the development of evidenced-based interventions to prevent them from occurring in the 
future. 
Methods 
Identification of studies 
Searches were carried out on 11th December 2014 using the databases: Web of 
Science, Scopus, Medline, PsychINFO, Ovid, and Global health. The search terms consisted 
RI³QRFHER´RU³SODFHERHIIHFW´DQGZKHUHDYDLODEOHVHDUFKHVZHUHOLPLWHGWRVWXGLHVZLWKD
human sample, with review articles restricted. The reference sections of included studies 
were also examined as well as papers suggested through personal contacts. No grey literature 
was searched and no temporal constraints were used. The review followed a previously 
designed, unpublished protocol. 
Selection criteria 
Studies were eligible for inclusion if they met the following criteria: 
x Studied a human population (healthy volunteers, patients or children were 
allowed). 
x Used an experimental or prospective design.  
x Used an inert exposure, i.e. containing no pharmacological or physiological active 
ingredient.  
x Assessed factors on their ability to predict symptom reporting, and these factors 
could be baseline characteristics or experimentally induced.  
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x Included an outcome of symptom reporting after participants received an inert 
exposure. Reported symptoms must not have been due to an active exposure (e.g. 
studies where an inert exposure was applied after an active exposure such as heat 
stimulation were excluded, as in this case the symptoms would have resulted from 
the heat stimulation). 
x Measured symptoms via self-report or inferred through objective measures (e.g. 
scratching behaviour).  Such symptoms could be somatic, a measure of arousal or 
mood. Because of the difficulty in defining when an outcome is aversive or 
beneficial we took an inclusive approach. For example measures of alertness 
(where an increase could be aversive in some instances) or contentedness (where 
decreases might be possible) were both included.  
x Publish in any language.  
Data extraction  
For each study included in the review, details relating to 20 issues were extracted. In 
summary these related to: sample characteristics, methodological design, type of exposure, 
experimental conditions and/or baseline risk factors, symptom measurement, statistical 
analysis and results. Any non-english articles were translated. We differentiated between 
studies that used an experimental or a prospective design in order to easily identify factors 
implicated in nocebo effects that can be manipulated and those that naturally occur at 
baseline. For a copy of the data extraction sheet used, see Appendix 1. 
Quality assessment  
Eligible studies using an experimental design were assessed using the Cochrane 
&ROODERUDWLRQ¶V5LVNRI%LDVWRRO(Higgins et al., 2011). For prospective studies, the CASPin 
(1998) critiFDODSSUDLVDOWRROZDVXVHGDQGDGDSWHGWRJLYHDµKLJK¶µXQFOHDU¶RUµORZ¶ULVNRI
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bias score, which were colour coded red, orange and green respectively. Originally the CASP 
is scored with yes/no answers but this was re-scored to low risk (yes) and high risk (no) as 
wells as including an unclear risk response for when enough information was not provided, 
similar to the Cochrane Risk of Bias tool. As these tools had no criteria assessing sample size 
we looked at this separately. 
Review process 
RKW conducted the database searches and screened the titles and abstracts of articles 
to assess their potential relevance. Guidance was obtained from GJR if there was any 
uncertainty as to including an article for full text review. RKW obtained the full articles for 
those citations that appeared potentially relevant and checked them against the inclusion 
criteria. If it was unclear whether an article met the inclusion criteria, consensus was sought 
from GJR and JW. RKW then independently extracted data for each included study and 
carried out the quality assessment with guidance from GJR. Due to the expected 
heterogeneity in the studies we did not plan for any meta-analyses and instead we used a 
narrative synthesis. There is no general consensus on the best way to carry out a narrative 
synthesis for systematic reviews (Popay et al., 2006). As such we decided to use a weight of 
evidence approach. To do this, we identified the strength of evidence for each risk factor 
based on the number of studies investigating each risk factors and their respective quality. 
Results 
Search results 
The database search retrieved 12582 citations. After removing duplicates 6585 
citations remained. After screening titles and abstracts, we reviewed the full text of 88 articles 
relating to 96 studies. Of these, 13 studies were excluded for not investigating any risk factors 
for the development of symptoms, nine were excluded for using an active exposure and seven 
were excluded for not measuring symptoms. Sixty-six articles met the inclusion criteria. 
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Twenty-one additional articles were identified by reference checks of included articles and 
through personal contacts; resulting in a total of 87 articles. Two articles reported results on 
two separate studies each (Walach & Schneider, 2009; Winters et al., 2001) and are referred 
WRDVµ([S¶RUµ([S¶ZKHUHQHFHVVDU\leaving 87 articles reporting on 89 studies. Of 
these, 70 were experimental (see table 1) and 19 prospective (see table 2). Figure 1 provides a 
flow diagram of the study selection according to the Preferred Reporting for Systematic 
Reviews and Meta-analyses statement (Moher, Liberati, Tetzlaff, & Altman, 2009).  
Quality assessment 
Experimental studies. The quality of experimental studies was poor (see figure 2), 
with the main problem being a lack of clear reporting. Thirty-six studies neglected to mention 
how they carried out randomisation while 22 studies were at high risk of bias for failing to 
mention if participants were randomised or for not using randomisation at all. Due to the 
unclear reporting of random sequence generation, the risk for allocation concealment bias 
followed a similar pattern. For blinding of participants and personnel, studies often failed to 
state if the experimenters were blind to the manipulation that accompanied the exposure, 
leaving the risk of bias unclear. Only six studies used adequate blinding procedures, with 12 
not using blinding at all. Sixty-five studies used self-report measures, as such blinding of the 
outcome assessment was judged to be unlikely to influence these results. For 52 studies, drop 
outs were not addressed, or if they were, they typically failed to explain how this affected the 
results, leaving the risk of bias unclear. Only one study had lodged a protocol in a publically 
accessible registry prior to the start of recruitment leaving us unable to assess the risk for 
selective reporting for the remaining studies. As well as this we looked for justification of 
sample size to assess if each study was adequately powered. Again this was poorly addressed 
with only 9 out of the 70 studies mentioning that they carried out an a priori sample size 
calculation.  
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Prospective studies. The prospective studies performed well against the quality 
check (see figure 2). All studies addressed a clearly focused issue with a standardised 
exposure across all participants. Studies often lacked information about how participants 
were recruited. However, self-report measures were widely used to minimise bias from 
experimenters. The identification and control of confounding factors was only deemed an 
issue for six studies that neglected to control for demographic factors such as gender or age 
and past symptom reporting. The follow up of participants was judged to be appropriate in 16 
studies. Regarding the generalisability of the findings, it was often difficult to know if the 
results could be applied to the population being studied due to the insufficient information 
about how participants were recruited. In addition, similarly to the experimental studies, 
justification for sample size was limited with only one study providing an a priori sample size 
calculation. 
A. Experimentally induced risk factors categories 
 Seventy experimental studies were included that investigated risk factors which fell 
into 9 different categories as discussed below (further details in supplementary tables 3-11).  
Learning. Twenty three studies manipulated different types of learning on symptom 
reporting finding some evidence for its role in nocebo effects. Four of these investigated prior 
experience of which two lower quality studies found no significant effects (Bayer, Coverdale, 
Chiang, & Bangs, 1998; Dinnerstein & Halm, 1970). However, Andre-Obadia, Magnin, and 
Garcia-Larrea (2011) VKRZHGWKDWVKDPU706WHQGHGWRZRUVHQSDWLHQWV¶SDLQZKHQ
following an active yet unsuccessful rTMS treatment (however caution is required as no 
statistical test accompanied this finding), and a high quality study by Stegen et al. (1998) 
found that participants reported significantly more arousal and respiratory symptoms when 
completing a breathing trial with room air before a breathing trial with carbon dioxide rather 
than afterwards. As such there is some evidence that prior experience is involved in the 
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development of nocebo effects. Two studies of mixed quality explored the impact of implicit 
association supporting its role in the nocebo effect, finding that drinking sham caffeine in a 
coffee solution resulted in significantly more alertness, contentedness, and arousal, than 
drinking sham caffeine in an orange juice solution (Flaten & Blumenthal, 1999; Mikalsen, 
Bertelsen, & Flaten, 2001).  Three studies of high quality investigated learning through the 
manipulation of social observation, with two finding a significant effect, broadly supporting 
its role in the nocebo effect. Lorber, Mazzoni, and Kirsch (2007) failed to show any main 
effects of observing a confederate display symptom behaviours after inhaling a sham 
environmental toxin which they were also exposed to. However, in a similar study, 
participants who observed a confederate display symptoms had significantly higher symptom 
ratings after inhalation than participants who did not (Mazzoni, Foan, Hyland, & Kirsch, 
2010). Similarly, patients who watched a video of people scratching compared to those who 
saw a video of people sitting idle had higher itch and scratching behaviour rating after 
administration of sham histamine (Papoiu, Wang, Coghill, Chan, & Yosipovitch, 2011), no 
results were reported for the healthy volunteers in this study. 
Of the remaining 14 studies, 13 investigated learning by using classical conditioning 
to pair inert exposures such as odours with CO2 inhalation before presenting the inert 
exposures on their own (De Peuter et al., 2005; Devriese, De Peuter, Van Diest, Van de 
Woestijne, & Van den Bergh, 2006; Devriese et al., 2000; Devriese et al., 2004; Meulders et 
al., 2010; Van den Bergh, Kempynck, van de Woestijne, Baeyens, & Eelen, 1995; Van den 
Bergh, Stegen, & Van de Woestijne, 1997, 1998; Van den Bergh et al., 1999; Van Diest et 
al., 2006; Winters et al., 2001 exp 1 and 2; Winters et al., 2003). Six studies of mixed quality 
found significant effects of classical conditioning and although seven found no main effect of 
conditioning on symptom reporting, six of these were of lower quality. As such there is some 
evidence for the role of classical conditioning in nocebo effects, and that this learning effect 
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can be generalised to new odours (Devriese et al., 2000; Van den Bergh et al., 1997, 1998).  
However odour type alone, without classical conditioning is not enough to elicit symptoms as 
demonstrated in this group of studies and the remaining study in this category (Dalton, 1999). 
Perceived dose. Six studies manipulated participant perceptions of the dose of the 
exposure that they received. Four of these found significant effects with three being of higher 
quality, broadly supporting a link between higher perceived dose and nocebo effects. Only 
two studies found no significant effects of dose related to decaffeinated coffee consumption 
(Flaten, Aasli, & Blumenthal, 2003) or taking a sham sedative pill (Jensen & Karoly, 1991).  
The remaining four all demonstrated significant main effects: Increasing the setting on a 
sham shock generator increased pain intensity ratings in two studies (Bayer, Baer, & Early, 
1991; Bayer et al., 1998), tension scores increased as a function of perceived dose following 
decaffeinated coffee consumption in one study (Kirsch & Weixel, 1988), and in a final study 
being told that a sham EMF exposure would be strong resulted in a higher overall symptom 
scores compared to being told the exposure would be weak (Szemerszky, Koteles, Lihi, & 
Bardos, 2010).  
Self-awareness. Four studies manipulated self-awareness during exposure. Three 
higher quality studies found no significant effects with only one lower quality study reporting 
an effect. As such there is little evidence that self-awareness increases the likelihood of a 
nocebo effect. Both Geers, Helfer, et al. (2005) and Geers, Helfer, Weiland, and Kosbab 
(2006) showed no significant main effects of instructing participants to attend to any 
symptoms or sensations they experienced. Using a distraction task also did not have a 
significant effect on symptom reporting (Van den Bergh et al., 1998) .Gibbons, Carver, 
Scheier, and Hormuth (1979) however, did find a significant main effect, with participants 
facing a mirror reporting less perceived arousal than participants not facing a mirror 
following ingestion of a sham drug. 
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Type of administration. Two studies of mixed quality tested whether type of 
administration affects symptom reporting, finding no evidence for a link with nocebo effects. 
There was no difference in symptom reporting between a sham pill and either a saline 
injection (Goldman, Witton, & Scherer, 1965) or sham acupuncture (Kaptchuk et al., 2006). 
Verbal suggestions on performance. Three studies manipulated verbal suggestions 
about the effect an inert exposure would have on performance. Two higher quality studies 
found no significant effects with only one lower quality study reporting an effect. As such 
there is little evidence that suggesting an exposure impairs performance increases the 
likelihood of a nocebo effect. Both Harrell and Juliano (2009) and Nevelsteen, Legros, and 
Crasson (2007) found no significant main effects of suggesting sham coffee or sham EMF 
would enhance or impair performance on a task on any of their symptom measures, 
respectively. However, smokers told that a sham cigarette would impair performance had 
significantly more craving symptoms than those who were told it would enhance performance 
(Harrell & Juliano, 2012).  
Verbal suggestions of likelihood of exposure. Nine studies manipulated suggestions 
about the likelihood that an exposure would occur. All studies were of higher quality with 
four finding significant effects and five finding non-significant effects. In other words, there 
was mixed evidence for the role of likelihood suggestions in nocebo effects. The studies used 
a mixture of conditions in which participants were either told they would receive an active 
exposure (deception), might receive an active or inactive exposure (double-blind), would 
receive an inactive exposure (open) or nothing (control).  Five of the studies found no 
significant main effects (Geers, Helfer, et al., 2005; Geers et al., 2006; Ossege et al., 2005; 
Walach, Schmidt, Dirhold, & Nosch, 2002; Walach & Schneider, 2009 exp 1). Geers, 
Wellman, Fowler, Rasinski, and Helfer (2011) however found that participants reported 
significantly more side effects in response to a sham pill when given deceptive information, 
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compared to double-blind or control information. In addition, participants given deceptive or 
double-blind suggestions had a significantly higher increase in alertness following ingestion 
of sham coffee (Kirsch & Weixel, 1988) and a significantly higher number of adverse events 
following a sham weight loss supplement  (Tippens et al., 2014) than participants in the 
control condition. For Walach, Schmidt, Bihr, and Wiesch (2001) participants told they 
would receive an inactive exposure scored higher on general wellbeing than those who 
received no substance or instruction. 
Verbal suggestions of arousal. Sixteen studies manipulated suggestions about the 
effect an inert exposure would have on arousal. Thirteen studies showed a significant effect, 
with 10 of these being of higher quality. This strongly supports a link with nocebo effects. 
Only three studies revealed no main effects (Brondeur, 1965; Kuenzel, Blanchette, Zandstra, 
Thomas, & El-Deredy, 2012; Penick & Fisher, 1965). The remaining 13 all demonstrated 
significant effects. Participants given stimulant suggestions compared to sedative suggestions 
had higher tension scores and were more lively after administration of a sham drug (Flaten, 
Simonsen, & Olsen, 1999; Mrna & Skrivanek, 1985), and had higher scores of stress, arousal, 
alertness, friendliness and aggressiveness, and lower fatigue scores after ingestion of an inert 
drink (Dinnerstein & Halm, 1970; Flaten, 1998; Slanska, Tikal, Hvizdosova, & Benesova, 
1974). Higuchi, Shoji, and Hatayama (2002) demonstrated lower stress and stimulant 
symptoms for participants given relaxing suggestions compared to no information for 
lavender and jasmine fragrances respectively. Goldman et al. (1965) found that more patients 
reported suggested drug effects in a sedative condition than in a stimulant condition. The 
remaining studies found a significant increase in caffeine related symptoms (Geers, Weiland, 
Kosbab, Landry, & Helfer, 2005; Lotshaw, Bradley, & Brooks, 1996), and alertness 
(Schneider et al., 2006; Walach & Schneider, 2009 exp 2) and a significant decrease in 
calmness (Mikalsen et al., 2001) for participants told they would receive caffeine compared 
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to participants who were told they would not receive caffeine or who received no beverage. 
Finally Angelucci and Pena (1997) found that participants given coffee with low arousal 
expectations had significantly lower alertness compared to participants given coffee with no 
expectations, high arousal expectations or no coffee at all.  
Verbal suggestions of symptoms. Twenty one studies manipulated suggestions about 
what symptoms to expect from an inert exposure. Thirteen found a significant effect, with 11 
of these being of higher quality, broadly supporting a link with nocebo effects. Out of the 21 
studies, eight reported no significant main effects (Devriese et al., 2006; Devriese et al., 
2004; Heatherton, Polivy, & Herman, 1989; Jaen & Dalton, 2014; Schweiger & Parducci, 
1981; Walach et al., 2002; Winters et al., 2003; Witthöft & Rubin, 2013). For the remaining 
13 studies, Benedetti, Amanzio, Casadio, Oliaro, and Maggi (1997), Wise et al. (2009), 
Crichton, Dodd, Schmid, Gamble, and Petrie (2014) and  Pennebaker and Skelton (1981) 
found significantly higher symptoms scores for those warned about side effects compared to 
those not warned after administration of sham treatment, infrasound and ultrasonic noise 
respectively. Dalton (1999), Neukirch and Colagiuri (2014) and Put et al. (2004) found that 
SDUWLFLSDQWV¶Vymptoms were significantly consistent with the warning they received about an 
odour, sham sleep medication and sham inhaler respectively. Three studies demonstrated that 
participants experienced significantly more symptoms when informed about side effects to a 
sham drug (Gibbons et al., 1979; Zimmermann-Viehoff et al., 2013) or saline eye drops 
(Gavrylyuk, Ehrt, & Meissner, 2010) compared to being informed it was a placebo. Similarly 
both Bayer et al. (1991) and Read and Bohr (2014) established significantly higher symptoms 
scores for those informed they would receive an active compared to an inactive exposure. 
Colagiuri, McGuinness, Boakes, and Butow (2012) however found the opposite, participants 
not warned about the side effects experienced more and a greater severity of side effects than 
those warned about one or four side effects.  
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Miscellaneous. Six studies looked at factors that did not fit into the above categories. 
There was no significant effect of manipulating participants to cooperate (Geers, Weiland, et 
al., 2005) RUWKHH[SHULPHQWHUV¶H[SHFWDWLRQVRISDUWLFLSDQWV¶V\PSWRPV(Walach et al., 2001). 
However, Faasse, Cundy, Gamble, and Petrie (2013) found that manipulating tablet brand to 
make participants think they had changed to a generic version resulted in a significantly 
higher number of symptoms compared to participants told that they were still taking the 
original branded tablet, although this study was of lower quality than the others in this group. 
Jensen and Karoly (1991) have shown that manipulating social desirability so that 
participants think responding to the pill is more socially desirable results in significantly 
higher symptom scores. Type of breathing has also been shown to affect symptom reporting 
with normocapnic overbreathing resulting in higher respiratory symptoms compared to 
spontaneous breathing (Van Diest et al., 2006). Lastly, a conditioned odour results in more 
symptoms if the odour is presented immediately rather than a week after conditioning trials 
(Devriese et al., 2000). 
B. Baseline risk factors categories 
Nineteen prospective studies and also 33 experimental studies which assessed 
baseline risk factors were included which fell into six different categories as discussed below 
(further details in supplementary tables 12-17).  
Demographics. Twenty-one studies looked at the risk of demographic characteristics, 
finding no demonstrable evidence for their role in nocebo effects. Five of these investigated 
age and found it did not predict any symptom outcomes (de la Cruz, Hui, Parsons, & Bruera, 
2010; Geers, Helfer, et al., 2005; Goetz et al., 2008; Lombardi, Gargioni, Canonica, & 
Passalacqua, 2008; Witthöft & Rubin, 2013). As four of these studies were of higher quality, 
this is good evidence that age is not linked with the development of nocebo effects. Eighteen 
studies (Angelucci & Pena, 1997; Casper, Tollefson, & Nilsson, 2001; Geers, Helfer, et al., 
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2005; Geers et al., 2011; Goetz et al., 2008; Harrell & Juliano, 2012; Jensen & Karoly, 1991; 
Liccardi et al., 2004; Lombardi et al., 2008; Lorber et al., 2007; Mazzoni et al., 2010; Papoiu 
et al., 2011; Read & Bohr, 2014; Strohle, 2000; Van den Bergh et al., 1997, 1998; Witthöft & 
Rubin, 2013) looked at gender and only four reported significant results suggesting women 
are more susceptible to nocebo effects than men (Casper et al., 2001; Liccardi et al., 2004; 
Strohle, 2000; Szemerszky et al., 2010). Of the remaining 14 showing non-significant effects, 
12 were of high quality suggesting there is very little evidence for the role of gender in 
nocebo effects. The effects of level of education (de la Cruz et al., 2010; Witthöft & Rubin, 
2013) were equivocal in two high quality studies, whereas employment (Drici, Raybaud, 
Delunardo, Iacono, & Gustovic, 1995), was not a significant predictor. 
Clinical Characteristics. Fourteen studies investigated clinical characteristics, finding 
mixed evidence for a link with nocebo effects. Six studies of high quality looked at the effect 
of baseline symptom scores, finding mixed evidence for a link with nocebo effects. Two 
found no significant effects (Andre-Obadia et al., 2011; Casper et al., 2001). For the other 
four, results were mixed. Danker-Hopfe, Dorn, Bornkessel, and Sauter (2010) and de la Cruz 
et al. (2010) found that higher symptom scores at baseline predicted higher symptom scores 
after exposure to sham EMF and treatment respectively, whereas Flaten et al. (2003) and 
Goetz et al. (2008) found the opposite after drinking decaffeinated coffee and taking sham 
PHGLFDWLRQIRU3DUNLQVRQ¶VUHVSHFWLYHO\6L[VWXGLHVof high quality looked at the effect of 
type of clinical condition, with five finding a significant effect. They showed that suffering 
from a condition that is exacerbated by the suggested sham exposure significantly increased 
symptom reporting compared to healthy volunteers, strongly supporting a link with nocebo 
effects. Nevelsteen et al. (2007) found that depression did not predict symptoms in response 
to a sham magnetic field. However,  Papoiu et al. (2011), Strohle (2000), De Peuter et al. 
(2005) and Bogaerts et al. (2010) showed that suffering from atopic dermatitis, panic 
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disorder, asthma or medically unexplained dyspnea  resulted in significantly more symptoms 
in response to sham histamine, sham panic disorder trigger, sham inhaler and breathing trials 
with room air, respectively, compared to healthy volunteers. In addition Szemerszky et al. 
(2010) found that the level of perceived sensitivity to EMFs was positively correlated with 
symptom scores after sham EMF exposure. The remaining two studies looked at previous 
drug reactions finding weak evidence for a link with nocebo effects. Lombardi et al. (2008) 
found no significant effects of type or severity of previous drug reaction on symptoms in 
response to a sham allergen pill. However, a higher quality study by Mrna and Skrivanek 
(1985) found the reaction to another sham drug was significantly correlated with perceived 
drug effect. 
Expectations. Thirteen studies looked at the effect of participant expectations on 
symptom reporting, broadly supporting a link with nocebo effects. Eleven of these studies 
ORRNHGDWSDUWLFLSDQWV¶V\PSWRPH[SHFWDWLRQVRIZKLFKILYHhigher quality studies revealed 
no significant effects (Angelucci & Pena, 1997; Molcan & et al., 1982; Walach et al., 2001; 
Walach & Schneider, 2009 exp 1 and 2). The remaining six studies demonstrated that 
expectations of symptoms significantly predicted (Fillmore & Vogel-Sprott, 1992; Köteles & 
Babulka, 2014; Vase et al., 2013) or correlated (De Peuter et al., 2005; Flaten et al., 2003; 
Szemerszky et al., 2010) with symptom reporting.  Five of these studies were of higher 
quality therefore broadly supporting a link with nocebo effects. Three studies also looked at 
expectations in terms of the substance taken finding weak evidence for its role in nocebo 
effects. Link, Haggard, Kelly, and Forrer (2006) found that participants who believed they 
had taken an active pill reported more symptoms than those who thought they had a taken a 
sham pill, however this was a low quality study. Higher quality studies by Bayer et al. (1998) 
and Walach et al. (2001) also investigated this but found no significant effects. 
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Anxiety. Nine studies looked at the influence of anxiety on symptom reporting, 
finding weak evidence for a link with nocebo effects. Six studies of mixed quality looked at 
state anxiety (Bogaerts et al., 2010; Link et al., 2006; Molcan & et al., 1982; Nevelsteen et 
al., 2007; Szemerszky et al., 2010; Witthöft & Rubin, 2013) but only Nevelsteen et al. (2007) 
found a significant effect, with state anxiety predicting physical symptom scores. Molcan and 
et al. (1982) and Nevelsteen et al. (2007) found no significant effects of trait anxiety. 
Angelucci and Pena (1997) found combined state and trait anxiety scores significantly 
predicted anxiety, but did not report results for state and trait anxiety separately. However no 
such effect of combined state and trait anxiety was found on symptom reporting to an odour 
(Van den Bergh et al., 1997), although this was a lower quality study. Finally, a high quality 
study by Danker-Hopfe et al. (2010) found that anxiety towards a local base station predicted 
subjective sleep quality after sham EMF exposure. 
Personality. Twenty-two studies looked at different aspects of personality as 
predictors of symptoms. Twelve studies showed significant effects of personality of which 
only three were of low quality as such finding evidence broadly supporting a link with 
nocebo effects.  There were no significant effects of suggestibility (Angelucci & Pena, 1997), 
sensitivity to anxiety (Nevelsteen et al., 2007), restraint (Heatherton et al., 1989),  or social 
desirability (Link et al., 2006; Put et al., 2004; Stegen, Van Diest, Van de Woestijne, & Van 
den Bergh, 2000). However, studies did show significant effects of the following on at least 
one symptom outcome: Type A personalities reported more side effects than type B (Drici et 
al., 1995); pain catastrophizing positively correlated with side effect reports (Sullivan, Lynch, 
Clark, Mankovsky, & Sawynok, 2008); blunting behaviour predicted symptom reporting 
(Van den Bergh et al., 1997); positive affect and vigilance predicted symptom scores 
(Nevelsteen et al., 2007)³IUDLODQGVXEPLVVLYH´SHUVRQDOLW\FRUUHODWHGZLWKWKHH[SRVXUHV 
perceived effect (Slanska et al., 1974); somatisation and motivation predicted symptom score 
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(Szemerszky et al., 2010); and modern health worries and somatosensory amplification 
predicted symptom scores (Witthöft & Rubin, 2013). There was mixed evidence for the role 
of negative affect (Bogaerts et al., 2010; De Peuter et al., 2007; De Peuter et al., 2005; 
Devriese et al., 2000; Devriese et al., 2004; Nevelsteen et al., 2007; Put et al., 2004; Stegen et 
al., 1998; Stegen et al., 2000; Van den Bergh et al., 1995), neuroticism (Mazzoni et al., 2010; 
Davis, Ralevski, Kennedy, & Neitzert, 1995), and pessimism (Geers, Helfer, et al., 2005; 
Szemerszky et al., 2010). 
Miscellaneous. Thirteen studies looked at baseline factors which did not fit into the 
above categories. These included caffeine consumption (Geers, Weiland, et al., 2005; Geers 
et al., 2011), olfactory sensitivity (Dalton, 1999), perceived cue odour (Devriese et al., 2004), 
visibility of a mobile phone base station and pre-occupation with EMF (Danker-Hopfe et al., 
2010), geographical site of enrolment (Goetz et al., 2008), hospital centre (Liccardi et al., 
2004), stress experienced whilst wearing a helmet delivering sham EMF (Nevelsteen et al., 
2007), ability to predict which odour produced the most symptoms (Meulders et al., 2010) 
and risk perception (Nevelsteen et al., 2007),  which had no significant effects. Köteles and 
Babulka (2014) however found that odour pleasantness predicted perceived change in 
alertness for eucalyptus oil. In addition, odour reactivity predicted symptom responding to 
odours (Dalton, 1999) and high regard for medications positively correlated with perceived 
drug effect (Goldman et al., 1965).  Mazzoni et al. (2010) found that if the gender of the 
model matched the participant this predicted symptom development in social observation 
studies. Nevelsteen et al. (2007) found that less comfort under the helmet delivering the sham 
EMF predicted symptoms. Finally Wendt et al. (2014) reported that significantly more 
symptoms were reported in val/val homozygous carriers compared to val 158/Met 18 and 
Met/Met 158 homozygous carriers after sham treatment.  
C. Interactions between risk factor categories 
20 
 
As well as investigating the main effects of each risk factor, some studies assessed the 
interactions between risk factors, as displayed in the last column of tables 3-19. Those risk 
factors which were implicated often in these interactions were factors such as µlikelihood 
VXJJHVWLRQ¶which interacted ZLWKµSHVVLPLVP¶- participants given deceptive suggestions 
report more symptoms compared to those told it was an inactive pill, if they were pessimists 
(Geers, Helfer, et al., 2005)µVHOI-DZDUHQHVV¶- participants given deceptive suggestions 
reported more symptoms when asked to monitor their bodily sensations (Geers et al., 2006); 
DQGµSHUFHLYHGGRVH¶- tension increased with increasing coffee dose for those given 
deceptive suggestions, but decreased with increasing coffee dose when given double-blind 
suggestions (Kirsch & Weixel, 1988). 
,QDGGLWLRQµFODVVLFDOFRQGLWLRQLQJ¶ showed interactionVZLWKµRGRXU¶ pairing an 
odour with CO2 elicited symptoms to the odour alone, only if the odour was foul smelling 
(Devriese et al., 2000; Van den Bergh et al., 1995; Van den Bergh et al., 1997; Winters et al., 
2003). 7KLVLQWHUDFWLRQEHWZHHQµFODVVLFDOFRQGLWLRQLQJ¶DQGµRGRXU¶ZDVDOVRIRXQGWRPRUH
OLNHO\RFFXUDPRQJSHRSOHZLWKKLJKµQHJDWLYHDIIHFW¶(Devriese et al., 2000) and those 
manipulated to have higher µVHOI-DZDUHQHVV¶(Van den Bergh et al., 1998). Negative affect 
DOVRLQWHUDFWHGZLWKµV\PSWRPVXJJHVWLRQV¶ZLWKKLJKHUREVWUXFWLRQDQGG\VSQHDV\PSWRP
scores after suggestions of bronchoconstriction compared to bronchodilation for a sham 
inhaler if participants had high negative affect (Put et al., 2004). An interaction was also 
IRXQGZLWKµSULRUH[SHULHQFH¶ZLWKKLJKQHJDWLYHDIIHFWSDUWLFLSDQWVUHSRUWLQJPRUHDURXVDO
and symptoms on the whole to a room-air breathing trial when this preceded rather than 
followed a CO2 breathing trial (Stegen et al., 1998). 
As well as interacting with negative affect, symptom suggestions interacted with other 
IDFWRUV7KHVHLQFOXGHGµVHOI-DZDUHQHVV¶participants reported more symptoms when told 
they were taking an active drug with side effects if they were not facing a mirror (Gibbons et 
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al., 1979)µRGRXUV¶PRUHV\PSWRPUHSRUWVIROORZLQJVXJJHVWLRQRIV\PSWRPVLIWKHRGRXU
was unpleasant (Dalton, 1999)µFODVVLFDOFRQGLWLRQLQJ¶KLJKHUWRWDOUHVSLUDWRU\FDUGLDFDQG
unclassified symptom scores following exposure to an odour previously paired with CO2 if 
participants received symptom suggestions (Winters et al., 2003)DQGµVWDWHDQ[LHW\¶KLJKHU
total and head/concentration symptoms following symptom suggestions if participants had 
high anxiety (Witthöft & Rubin, 2013). 
Discussion 
Summary of main results 
From the 89 studies that met our inclusion criteria, 14 categories of risk factor for a 
nocebo effect were identified, including nine experimentally induced risk factor categories 
and six baseline risk factor categories. 2IWKHVHFDWHJRULHVµOHDUQLQJVRFLDOREVHUYDWLRQ¶
µSHUFHLYHGGRVH¶µYHUEDOVXJJHVWLRQVRIDURXVDODQGV\PSWRPV¶DQGµEDVHOLQHsymptom 
H[SHFWDWLRQV¶DSSHDUHGWREHWKHVWURQJHVWSUHGLFWRUVRIQRFHERHIIHFWV7KHUHZDVVRPH
HYLGHQFHIRUWKHUROHRIµSHUVRQDOLW\¶LQQRFHERHIIHFWVKRZHYHUZKLFKIDFHWVRISHUVRQDOLW\
are more strongly linked with nocebo effects needs further research. In addition, although not 
strong predictors on their own, learning/classical conditioning, likelihood suggestion, self-
awareness and negative affect consistently interacted with other risk factors. 
Given the proposed psychological mechanisms behind nocebo effects it is perhaps 
unsurprising that these factors have been consistently identified in the literature. Specifically 
looking at the expectation mechanism, it is intuitive that verbal suggestions of symptoms can 
generate expectations of these effects leading to symptom reporting.  In support of this, 
participants¶RZQEDVHOLQHH[SHFWDWLRQVFDQtrigger symptoms, while perceived dose 
presumably affects symptom reports through a mediating effect of expectations, with a higher 
dose associated in a participDQW¶VPLQGZLWKDVWURQJHUHIIHFW7KLVFRXOGDOVRH[SODLQWKH
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significance of medication brand, with branded medication being generally expected by the 
public to be better quality than generic unbranded medication and therefore less likely to 
cause side effects (Faasse et al., 2013). Expectations could also explain why four studies 
which measured symptom reports both for pre-warned and non-warned symptoms found 
stronger effects for symptoms that had previously been suggested (Faasse et al., 2013; 
Gibbons et al., 1979; Lorber et al., 2007; Mazzoni et al., 2010). It also explains why no effect 
was found for performance suggestions, as this should not directly influence expectations of 
symptoms from the exposure. 
It is important not to over-emphasise the nature of our results with respect to 
expectation, however. In particular, it was striking that type of administration and verbal 
suggestions of the likelihood of exposure did not appear to be relevant despite both 
supposedly raising expectations of symptoms. Possibly, the influence of these factors on 
expectations is weaker than might be thought. Alternatively, methodological factors may 
account for the lack of effect. For example, both studies assessing type of administration used 
patient samples (Goldman et al., 1965; Kaptchuk et al., 2006). Given their greater experience 
with medical procedures, merely changing an intervention from a pill to an injection may not 
have triggered a substantial change in expectations. For three of the likelihood suggestion 
studies (Walach et al., 2001; Walach et al., 2002; Walach & Schneider, 2009 exp 1) it was 
suggested that the absence of an effect could have been because of cultural differences, with 
the caffeine effect stereotype not as strong in Germany as it is in the USA.  
The overall support for the role of expectations identified in our review still allows for 
DWOHDVWWZRµVXE-PHFKDQLVPV¶WRH[LVW7KHILUVWLVDUROHIRUDWWHQWLRQDOELDVDQGV\PSWRP
detection (Hahn, 1997). The second is a more direct effect, where-by expectations affect 
emotional state (Kirsch, 1997b; Stewart-Williams, 2004). For example Kirsch (1997b) 
pointed out that the expectation of anxiety is likely to be anxiety provoking, thereby directly 
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causing the outcome. This could explain the strong results seen for manipulating verbal 
suggestions of arousal on symptom reporting, as the expectation of arousal or relaxation is 
itself likely to be arousing or relaxing. However, there does need to be a degree of caution in 
interpreting these results on arousal as they could be interpreted as part of the placebo 
response.  
With regards to misattribution as a mechanism, the evidence from the studies that 
investigated self-awareness as a risk factor did not support this, with the two most directly 
relevant studies that instructed participants to monitor for any sensations failing to find an 
effect. Equally, for the six studies investigating the effect of baseline symptoms on symptom 
reporting the results were mixed providing inconclusive support for misattribution.  However 
five studies (Bogaerts et al., 2010; De Peuter et al., 2005; Papoiu et al., 2011; Strohle, 2000; 
Szemerszky et al., 2010),  showed that suffering from a condition with symptoms similar to 
those being induced was a predictor of symptom reporting. As such while the mechanism 
remains plausible, further evidence is required to clarify its importance.  
For the learning mechanism support was found from studies investigating the risk 
IDFWRUµDVVRFLDWLRQ¶ with the taste of decaffeinated coffee being enough to elicit caffeine 
related symptoms (Flaten & Blumenthal, 1999; Mikalsen et al., 2001). For prior experience, 
the results were weak but this could have been due to a lack of experience as this 
manipulation was typically a one off event. However, there was evidence for the role of 
social observation, with two out of three studies showing a significant effect. In addition, 
support for learning was seen in the studies using classical conditioning, which involved a 
number of trials. Almost half of the studies showed that conditioning CO2 inhalation with 
any odour is enough to elicit symptoms to the odour itself, and a reliable finding amongst the 
studies was that this was especially the case if the odour was unpleasant.    
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For baseline risk factors, we found no evidence of any effects of gender. However, 
since conducting the literature search, one additional study that would have met the inclusion 
criteria has become apparent and which is relevant here. This study by Faasse, Grey, Jordan, 
Garland, and Petrie (2015) investigated the risk factor of observing a female confederate 
display symptoms, demonstrating a significant effect on symptom reporting in females. It is 
interesting to note that Lorber et al. (2007), who also studied social observation, also only 
found a significant effect in females. One possibility is that it may be something inherent to 
social observation that makes females more vulnerable to nocebo effects. Other demographic 
factors such as age, employment status or level of education were also not risk factors. 
Interestingly, anxiety did not come out as a strong predictor despite the role it could play 
through misattribution (generating physical symptoms that are available to be misattributed) 
and expectations (apprehension of symptoms). One possible explanation for this advanced by 
Szemerszky et al. (2010) is that scores of anxiety could reach a ceiling effect due to advance 
information about the risks of taking part in the study. For other baseline risk factors, many 
different types of personality were implicated such as: type A personality (Drici et al., 1995), 
lower positive affect, vigilance (Nevelsteen et al., 2007), pessimism, motivation to cooperate, 
somatisation, somatosensory amplification, modern health worries (Szemerszky et al., 2010; 
Witthöft & Rubin, 2013), and neuroticism (Davis et al., 1995). A lack of consistency in the 
personality traits studied makes it difficult to interpret these findings, but many would seem 
to fit with expectation and / or misattribution mechanisms.  
1RFHERHIIHFWVKDYHRFFDVLRQDOO\EHHQUHIHUUHGWRDVWKHµHYLOWZLQ¶RISODFHERHIIHFWV
If true, one would expect the risk factors for a nocebo effect to be the inverse of the risk 
factors for a placebo effect. At a first look the mechanisms supported in our review do appear 
to be similar to those previously identified for placebo effects, albeit acting in the opposite 
direction. For example, the expectancy mechanism has been implicated for placebos through 
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factors such as verbal suggestions, and participaQWV¶RZQEDVHOLQHH[SHFWDWLRQVZKLFKOHDGWR
positive expectations for pain or symptom relief (Benedetti et al., 2003; Kam-Hansen et al., 
2014; Price et al., 1999; Vits et al., 2013). In addition, learning mechanisms such as prior 
experience of pain relief, social observation or conditioning people to experience pain relief 
results in subsequent placebo responses (Colloca & Benedetti, 2006; Colloca & Benedetti, 
2009; Suchman & Ader, 1992). It also seems that opposite personality characteristics also 
predict placebo responding e.g. optimism (Geers, Kosbab, Helfer, Weiland, & Wellman, 
2007) as opposed to pessimism. One notable exception, however, would be the misattribution 
of pre-existing symptoms, as logically this can only be relevant for nocebo: one cannot 
misattribute the absence of pre-existing symptoms to an exposure. However it is possible one 
could misattribute and fixate on a coincidental decline in symptoms after taking a sham 
tablet, and misattribute their improved wellbeing to the tablet.  
Quality of original research 
It is possible that some of our conclusions may be due to differences in quality 
between those studies that found an effect and those that did not. We did not observe any 
clear trend for lower quality studies to report more or fewer significant results than higher 
quality studies. However, on the whole the quality of the studies included in this review was 
limited due to poor reporting of key issues in experimental research such as randomisation, 
allocation concealment, blinding, and not registering a study protocol prior to initiating 
recruitment. Prospective studies had fewer quality concerns, however given that experimental 
studies allow the control of more variables the results of these have more weighting than 
those from the prospective studies. It is also worth noting that almost half of studies did not 
mention receiving ethical approval. In an area of research requiring deception, or at least, 
withholding information in order to deliberately cause symptoms, this is surprising. There is 
scope for future researchers to improve the methodological rigour of this field. Another 
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surprising limitation of many of the studies included in this review was the lack of a priori 
sample size calculations. Only 10 out of 89 studies included in this review mentioned 
carrying out a sample size calculation in order to make sure the sample was adequately 
powered to test their research question(s). As such we could not assess the quality of studies 
based on their sample size in the large majority cases. Although it would have been useful to 
score each study for their strength of evidence, due to this lack of clear reporting and the 
heterogeneity across studies it was too hard to quantify the strength of each study using the 
same scale. 
Quality of this review 
A strength of this review is that we did not include studies in which participants were 
exposed to an active exposure capable of eliciting symptoms through physiological 
mechanisms (e.g. experiments altering the information given to participants about a genuine 
medication). Such studies do not assess the pure nocebo effect, described as the undesirable 
effects experienced from an inert exposure (Kennedy, 1961) and can prove more difficult to 
interpret (Neukirch & Colagiuri, 2014).  
Our search resulted iQDODUJHQXPEHURIUHVXOWV$VWKHWHUPµQRFHER¶LVVWLOOQRW
widely used and may be preferentially used by those studies identifying a significant increase 
in symptoms in their participants, we deliberately adopted a broader search strategy than that 
used in previous reviews, e.g. Petersen et al. (2014). Despite this, it is not certain every study 
that met the inclusion criteria has been included, especially as nearly a quarter of included 
studies were identified through personal contacts. This inconsistent use of terminology makes 
the nocebo literature difficult to search and will continue to limit reviews in this area. We 
could have LQFOXGHGWHUPVVXFKDVµDGYHUVHHIIHFWVRUQHJDWLYHRXWFRPH¶in the search 
strategy but the number of results would be unmanageable as it would include many clinical 
trials that would not meet our inclusion criteria. On medline alone, such search terms return 
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over 9UHVXOWV7KLVLVDOVRRQHRIWKHUHDVRQVZK\ZHGLGQRWVLPSO\XVHµSODFHER¶DV
one of the search terms ± HYHU\VWXG\ZKLFKGHVFULEHGLWVHOIDV³SODFHER-FRQWUROOHG´ZRXOGEH
returned. 
In addition to limitations resulting from our search strategy, it is possible that some 
studies could have been falsely rejected after title and abstract screening (e.g. the main 
purpose of the study may have been on the placebo effect and therefore only placebo and not 
nocebo findings were reported in the abstract). We suspect that this is unlikely to have 
occurred often, however. In order to have been included such studies would have had to a) 
manipulated factor(s) in order to affect nocebo responding or b) looked at baseline measures 
as predictors of nocebo responding, which many do not do. Many studies which looked at the 
placebo effect passed through abstract screening as they mentioned participants experiencing 
negative symptoms or patients feeling worse after placebo exposure. However, going through 
the full manuscript the majority of these studies would not explore the possible reasons why, 
e.g. baseline predictors. Therefore we feel this is not something to be too concerned about.  
In addition studies published in non-European languages may have been less likely to 
have been identified as well as studies that were not reported in the conventional peer-
reviewed literature.  
Other limitations of the review reflect the way we grouped the results. We aggregated 
studies based on the independent variable. Because of this and due to the fact that there are no 
direct replications each risk factor grouping contains several different outcomes. It is possible 
that an interaction exists between independent and dependent variables: for example, some 
outcomes may be more susceptible to the effects of changes in expectations than others.  
Unfortunately, we did not have enough data to explore this in depth.  
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Similarly as this review focused on identifying all the possible risk factors of nocebo 
effects that have been investigated in the literature, we included studies with different 
research populations, e.g. students, healthy volunteers and patients. As such there could be 
differences between the groups in terms of which mechanisms are more likely to be at play. 
For example, it is likely the misattribution mechanism is more important for the development 
of nocebo effects in patient samples than healthy volunteers. However, looking at studies that 
had a patient sample we should interpret the results of those that just focused on baseline 
disease measures as support of the misattribution mechanism with caution. These studies did 
not measure actual baseline symptoms or emotions which are more likely to be subject to the 
misattribution mechanism, rather than disease status.  
Finally, the interaction between the mechanisms, outcomes and mode of delivery may 
also be important, but could not be explored in detail given the data available to us. For 
example, different forms of sham intervention e.g. sham tablets vs sham caffeine vs sham 
EMF, may be more or less likely to trigger certain psychological mechanisms, and be more or 
less likely to affect certain outcomes, e.g. Szermersky, Dömötör , Berkes and Koteles (2016). 
Implications for clinical practice and research 
Our results suggest clinicians keen to reduce side effects induced by any nocebo 
effect associated with their interventions could: 1) identify patient expectations of the adverse 
effects of an intervention and provide reassurance if these seem excessive; 2) avoid giving 
suggestions of side effects associated with the intervention; 3) down-play the dose that is 
being provided; 4) reduce patient exposure to other patients experiencing side effects. Wells 
and Kaptchuk (2012) suggest the use of contextualised informed consent, whereby doctors 
should identify high risk patients and tailor the medication side effect information so that 
these patients only receive drug specific side effect information, which is less susceptible to 
the nocebo response. Our review supports this and suggests that such tailoring may be 
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especially required for those who have at-risk personality types. Clearly, these suggestions 
also have a downside, however, as they reduce informed consent and patient autonomy by 
restricting the information that is being provided. Alternative ways to reduce nocebo effects 
while maintaining the ability of a patient to give full informed consent are required. There is 
scope for researchers to develop innovative ways to reduce nocebo effects that does not 
require withholding of information. This has been shown by Crichton and Petrie (2015) who 
found that informing participants about nocebo effects effectively reduced symptoms to 
infrasound noise. In addition Bingel (2014) provides some suggestions on how to avoid 
nocebo effects which are supported by this review such as improving the communication in 
patient information leaflets to make them more patient-orientated and reduce negative 
expectations of potential adverse effects.  
Additional research should also aim to replicate risk factors which have so far 
received limited research, such as the more rarely investigated personality characteristics. It 
would also EHDGYLVDEOHWRORRNDJDLQDWWKHULVNIDFWRUµW\SHRIDGPLQLVWUDWLRQ¶LQDKHDOWK\
volunteer sample and to assess this manipulation on expectations to explore possible 
mechanisms.  It is also time for authors to use consistent terminology allowing easier 
identification of papers, and to enhance the quality of their research in this area. Simple acts 
such as being more explicit about randomisation and blinding procedures and publishing 
protocols will enhance the transparency of the research in this area whilst also helping to 
alleviate some of the controversy surrounding nocebo research. 
Conclusions 
This review found that there is a mix of factors which predict whether someone will 
H[SHULHQFHDQRFHERHIIHFW*LYHQWKHLPSOLFDWLRQVQRFHERHIIHFWVKDYHRQSDWLHQWV¶TXDOLW\RI
life and the health costs they create, it is important for research to start developing 
interventions to prevent nocebo effects from occurring whilst still trying to uphold informed 
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consent. This systematic review provides a useful starting point for researchers to develop 
evidenced based interventions designed to negate nocebo effects, whilst also highlighting 
areas that need further investigation and improvement.  
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Figure 1. Flow diagram of the selection process of studies including the number of events and 
reasons for exclusion.  
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Figure 2. Quality assessment of experimental and prospective studies 
  
a) Experimental studies 
b) Prospective studies 
SYSTEMATIC REVIEW OF NOCEBO EFFECT RISK FACTORS 
 
 
49 
 
Table 1. Summary of the methods used in the experimental studies 
Reference and 
quality 
Study 
design 
Population            
(N, Mean age, 
%Male) 
Inert 
exposure 
Experimental risk factor(s) and conditions Baseline risk factors 
Andre-Obadia 
et al. (2011)  
b,e 
RCT 
(B) 
Chronic 
neuropathic pain 
patients               
(45, 55.0, 37.8)     
Sham rTMS 1. Prior experience: a. Sham rTMS before active rTMS 
(20); b. Sham rTMS after successful active rTMS (12);        
c. Sham rTMS after ineffective active rTMS (13) 
Pain 
Angelucci and 
Pena (1997) 
e 
RCT 
(B) 
Student caffeine 
consumers          
(148, U/K, 23.0)   
Sham coffee 1. Arousal suggestions: a. Given coffee with no 
expectations (37); b. Given coffee with low arousal 
expectations (37); c. Given coffee with high arousal 
expectations (37); d. no coffee and no expectations (37) 
State and trait anxiety, 
Suggestibility, 
Expectations, Gender 
Bayer et al. 
(1991) 
e 
RCT   
(B+W) 
Unemployed 
Men                      
(100, U/K, 
100.0) 
Sham 
electrical 
shock 
1.Symptom suggestions: a. Told they would receive a 
safe but often painful undetectable current (60); b. Were 
assured there would be no shocks (40) 
2. Perceived dose: a. Within each group the stimulator 
setting increased from 0 to 80 mA 
None 
Bayer et al. 
(1998)  
a,e  
RCT 
(B+W) 
Job seekers            
(62, U/K, 82.0) 
Sham 
electrical 
shock 
1. Prior experience: a. Exposed to two physical pain 
induction procedures prior to sham stimulation (32); b. 
Warned of pain and received sham stimulation. They 
were not exposed to any prior pain induction (30) 
2. Perceived dose: a. Within each group the stimulator 
setting increased in steps of 10 every 5 minutes till it 
reached 50 
Expectations 
Benedetti et 
al. (1997) 
e 
RCT 
(B) 
Video assisted 
thoracoscopy 
patients                
(36, 53.7, 66.1) 
Sham 
treatment  
1. Symptom suggestions: a. Open injection that it would 
increase pain (18); b. Hidden injection (18) 
None 
Brodeur 
(1965) 
RCT 
(B) 
Healthy senior 
students                
Sham arousal 
capsule   
1. Arousal suggestions: a. Told it was a stimulant (15); b. 
Told it was a tranquilizer (15); c. No suggestion (15) 
None 
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e (45, U/K, 91.1) 
Colagiuri et al. 
(2012) 
e 
RCT 
(B) 
Students 
experiencing 
sleep difficulty      
(82, 20.2, 22.0) 
Sham 
sleeping pill  
1. Symptom suggestions: a. Treatment might cause one 
side effect (29); b. Treatment might cause four side 
effects (23); c. No warning about side effects (30) 
None 
Crichton et al. 
(2014) 
e 
RCT 
(B) 
Students              
(54, U/K, 37.0) 
Sham 
infrasound 
1. Symptom suggestions: a. TV footage detailing 
symptomatic experiences attributed to wind farms (27); 
b. TV footage with experts stating wind farms would not 
cause symptoms (27) 
None 
Dalton (1999) 
e 
RCT 
(B) 
Healthy 
volunteers 
(180, 31.7, 49.4) 
Odours 1. Odours: a. Pleasant smelling methyl salicylate (60); b. 
neutral smelling isobornyl acetate (60); c. Foul smelling 
butanol (60) 
2. Symptom suggestions: a. Told they would have 
relaxing effects (60); b. Told they were industrial 
solvents (60); c. Told they were approved for olfactory 
research (60) 
Odour reactivity, 
Olfactory sensitivity 
De Peuter et 
al. (2005) 
e 
RCT 
(W) 
Asthma patients 
and healthy 
controls  
(40, 23.9, 52.5) 
Sham inhaler 1. Conditioning: a. one sham inhaler paired with CO2 
challenge; b. one sham inhaler paired with O2 
Expectations, 
Negative affect, 
Clinical condition 
Devriese et al. 
(2000) 
a,e  
Non 
RCT 
(B+W) 
Healthy students 
(56, U/K, 41.1) 
Odours 1. Odour: a. Foul smelling ammonia; b. Pleasant smelling 
niaouli 
2. Conditioning: a. Ammonia paired with CO2 breathing 
task, Niaouli paired with room air breathing task (28); b. 
Ammonia paired with room air breathing task, Niaouli 
paired with CO2 breathing task (28) 
3. Timing: a. Test phase immediately after conditioning 
trials (28); b. Test phase one week after conditioning 
trials (28) 
4. Generalisation: a. New foul smelling odour butyric 
acid; b. New foul smelling odour acetic acid; c. New 
Negative affect 
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pleasant smelling odour citric aroma 
Devriese et al. 
(2004) 
a,e 
Non 
RCT 
(B+W) 
Healthy students 
(53, U/K, U/K) 
Odours 1. Odour: a. Foul smelling ammonia; b. Foul smelling 
butyric acid 
2. Conditioning: a. Ammonia paired with CO2 breathing 
task, butyric acid paired with room air breathing task 
(28); b. Ammonia paired with room air breathing task, 
butyric acid paired with CO2 breathing task (25) 
3. Symptom suggestions: a. Given information about 
possible health damaging effects of chemical pollution 
(U/K); b. No information (U/K) 
Negative affect, 
Perceived cue odour 
Devriese et al. 
(2006) 
 
RCT 
(B+W) 
Psychology 
students 
(40, U/K, 0.0) 
Odours 1. Odour: a. Foul smelling ammonia; b. Foul smelling 
acetic acid 
2. Conditioning : a. Ammonia paired with CO2 breathing 
task, acetic acid paired with room air breathing task (20); 
b. Ammonia paired with room air breathing task, acetic 
acid paired with CO2 breathing task (20) 
3. Symptom suggestions: a. Given information about 
possible health damaging effects of chemical pollution 
(20); b. No information (20) 
None 
Dinnerstein 
and Halm 
(1970) 
c,e 
RCT 
(B) 
Male students        
(80, U/K, 100.0) 
Sham arousal 
liquid 
1. Arousal suggestions: a. Told it was an energizer (40); 
b. Told it was a tranquilizer (40)     
2. Prior experience: a. Received aspirin prior to sham 
(40); b. Received lactose prior to sham (40)                          
None 
Faasse et al. 
(2013)  
b,c,e 
RCT 
(B) 
Healthy students   
(60, 19.4, 43.5) 
Sham anti-
anxiety tablet 
1. Brand suggestions: a. Branded reformulation change 
(20); b. Generic reformulation change (20); c.  No change 
(20) 
None 
Flaten (1998) 
e 
RCT 
(B) 
Healthy students   
(48, U/K, 35.4) 
Sham arousal 
drink 
1. Arousal suggestions: a. Told you will feel relaxed and 
sleepy (16); b. Told you will feel alert and a little stress 
(16); c. Told you will take an inactive drug (16) 
None 
Flaten and 
Blumenthal 
RCT 
(W) 
Healthy coffee 
drinkers 
Decaffeinate
d solution 
1. Association: a. Orange juice; b. Decaffeinated coffee None 
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(1999) 
e 
(21, 24.8, 61.9) 
Flaten et al. 
(1999) 
e 
RCT 
(B) 
Healthy 
volunteers in 
non-health 
professions          
(34, U/K, 54.5) 
Sham arousal 
capsule   
1. Arousal suggestions: a. The drug will make you feel 
relaxed (11); b. The drug will make you feel alert (12); c. 
You will receive capsules that contain a prescription drug 
(11) 
None 
Flaten et al. 
(2003)  
a,b,e 
W Coffee drinkers     
(20, U/K, 50.0) 
Sham 
coffee 
1. Perceived dose: a. Participants were first given one cup 
and then a second 
Symptoms, 
Expectations 
Gavrylyuk et 
al. (2010) 
e 
RCT 
(B) 
Healthy 
volunteers            
(30, 24.9, 32.0) 
Saline eye 
drops 
1. Symptom suggestions: a. Informed of pupil dilation 
effects (10); b. Informed of pupil constriction effects 
(10); c. Informed of saline eye drops (10) 
None 
Geers et al. 
(2006) 
e 
RCT 
(B)  
Healthy students   
(54, U/K, 31.5) 
Sham over-
the-counter 
pill 
1. Likelihood suggestions: a. Told the pill had unpleasant 
side effects (18); b. Told they may or may not receive the 
active drug (19); c. Told they would ingest an inactive 
drug (17)   
2. Self-awareness: a. Told to closely monitor 
feelings/bodily sensations (27); b. Not given any such 
instructions (27)  
None 
Geers et al. 
(2011) 
e 
RCT 
(B) 
Healthy students   
(102, 20.5, 21.6) 
Sham 
caffeine 
capsule 
1. Likelihood suggestions: a. Told it contained 250mg of 
caffeine (34); b. Told they may or may not be ingesting 
250mg of caffeine (34); c. Not given the capsule and 
received no caffeine expectation (34) 
Gender, Age, 
Caffeine 
consumptions 
Geers, Helfer, 
et al. (2005) 
e 
RCT 
(B)  
Healthy  
students          
(54, 21.0, 29.6)  
Sham over-
the-counter 
pill 
1. Likelihood suggestions: a. Told the pill had unpleasant 
side effects (18); b. Told the pill would make them feel 
either unpleasant or was an inactive substance (18); c. 
Told they would ingest an inactive pill (18) 
2. Self-awareness: a. Told to attend to any symptoms 
experienced (27); b. Not given any such instructions (27) 
Age, Gender, 
Optimism 
Geers, RCT Healthy students   Sham 1. Arousal suggestions: a. Told they were given caffeine Caffeine consumption 
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Weiland, et al. 
(2005) 
e 
(B) (57, U/K, 35.1) caffeine pill (U/K); b. No mention of caffeine (U/K) 
2. Cooperation prime: a. Given a scrambled sentence test 
with a cooperation prime (U/K); b. Given a scrambled 
sentence test with a neutral prime (U/K) 
Gibbons et al. 
(1979)  
a,e 
RCT 
(B)  
Female students    
(38, U/K, 0.0) 
Sham drug  1. Symptom suggestions: a. Told they were taking 
Cavanol which would produce some noticeable side 
effects (19); b. Told they were  taking baking soda (19) 
2. Self-awareness: a. Mirror was facing participants (19); 
b. Mirror was not facing participants (19) 
None 
Goldman et al. 
(1965)  
a,b,e 
Non 
RCT  
(B) 
Male veterans 
with 
schizophrenia      
(64, 44.0, 100.0) 
Sham arousal 
treatment  
1. Type of administration: a. Received sugar pill (32); b. 
Received saline injection (32) 
2. Arousal suggestoins: a. Told it would heighten their 
ward activity (32); b. Told it would lower their ward 
activity (32) 
Attitudes towards 
medication 
Harrell and 
Juliano (2009) 
c 
RCT  
(B)  
Adult non-
smoking coffee 
consumers    
(30, 22.6, 22.0) 
Sham coffee 1. Performance suggestions: a. Told caffeine enhances 
performance (15); b. Told caffeine impairs performance 
(15) 
None 
Harrell and 
Juliano (2012) 
c,e 
RCT  
(B)  
Adult smokers       
(43, 28.7, 67.4) 
Sham 
cigarette 
1. Performance suggestions: a. Told cigarette enhances 
performance (20); b. Told cigarette impairs performance 
(23) 
Gender 
Heatherton et 
al. (1989)  
e 
RCT  
(B)  
Female students    
(59, U/K, 0.0) 
Sham 
vitamin pill  
1. Symptom suggestions: a. Told vitamin has been 
reported to make people feel hungry (19); b. Told 
vitamin has been reported to make people feel full (20); 
c. Told no further information (20) 
Participant restraint 
Higuchi et al. 
(2002) 
e 
RCT 
(B) 
Healthy 
volunteers 
(30, 21.2, 40.0) 
Fragrance 
(Jasmine or 
Lavendar) 
1. Arousal suggestions: a. Told it was relaxing (10); b. 
Told it was stimulating (10); c. No information given 
(10) 
None 
Jaen and 
Dalton (2014) 
a,b,e 
Non 
RCT 
(B) 
Asthmatics            
(17, 38.5, 52.9) 
Sham active 
odour 
1. Symptom suggestions: a. Labelled the odour as 
therapeutic (9); b. Labelled the odour as asthmogenic (8) 
None 
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Jensen and 
Karoly (1991) 
e 
RCT    
(B+W)    
Students                
(86, U/K, 45.3) 
Sham 
sedative pill 
1. Social desirability: a. Type B personality is more 
positive then type A. Type B have been shown to respond 
more to pills (43): b. Relationship between type A and B 
personality and response to pills is very weak (43)     
2. Perceived dose: a. Suggestions of a high dose or low 
dose were counterbalanced across each group 
Gender 
Kaptchuk et 
al. (2006) 
RCT  
(B) 
  
Adults with 
distal pain in the 
arms                     
(266, 36.7, 45.9) 
Sham 
treatment  
1. Type of administration: a. Received sham acupuncture 
(133); b. Received placebo pill (133) 
None 
Kirsch and 
Weixel (1988) 
e 
RCT  
(B)  
Student coffee 
drinkers                
(U/K, 19.3, 
31.0) 
Sham coffee 1. Likelihood suggestions: a. Told they would receive 
coffee (U/K); b. Told they may or may not receive 
caffeinated coffee (U/K); c. No beverage, waited for 20 
minutes (U/K) 
2. Perceived dose: a. 1 tsp (U/K); b. 2 tsps (U/K); c. 3 
tsps (U/K); d. 5 tsps (U/K); e. 8 tsps (U/K)                  
None 
Kuenzel et al. 
(2012) 
e 
RCT 
(B) 
English 
speaking 
students  
(148, 21.7, 18.2) 
Herbal 
infusion tea 
1. Arousal suggestions: a. Told it would make them feel 
relaxed (45); b. Told it would make them feel active (53); 
c. No information given (50) 
None 
Lorber et al. 
(2007)  
e 
RCT  
(B) 
Students 
without upper 
respiratory 
conditions             
(86, U/K, 40.7) 
Sham 
environmenta
l toxin  
1. Social observation: a. Told inhaled substance has been 
reported to produce symptoms and observed a female 
confederate inhale and display symptoms (U/K); b. As 
above but no observation of confederate (U/K); c. Did 
not inhale the substance and observed a female 
confederate inhale and display symptoms (U/K); d. As 
above but no observation of confederate (U/K) 
Gender 
Lotshaw et al. 
(1996) 
e 
RCT 
(B) 
Male student 
coffee drinkers      
(50, U/K, 100.0) 
Sham 
coffee 
1. Arousal suggestions: a. Told coffee received 
decaffeinated (25); b. Told decaffeinated received 
decaffeinated (25) 
None 
Mazzoni et al. RCT Healthy students   Sham 1. Social observation: a. Observed a male/female Personality, Gender, 
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(2010) 
e 
(B) (120, 20.7, 50.0) environmenta
l toxin  
confederate inhale the substance and display symptoms 
(60); b. Did not observe a male or female confederate 
inhale the substance and display symptoms (60) 
Gender of model 
Meulders et al. 
(2010) 
a,e 
Non 
RCT 
(B+W) 
Healthy adults 
(58, 22.0, 48.3) 
Odours 1. Odour: a. Foul smelling ammonia; b. Foul smelling 
butyric acid 
2. Conditioning: a. Ammonia paired with CO2 breathing 
task, butyric acid paired with room air breathing task 
(29); b. Ammonia paired with room air breathing task, 
butyric acid paired with CO2 breathing task (29) 
Ability to predict 
which odour produced 
the most symptoms 
Mikalsen et al. 
(2001)  
e 
RCT 
(W) 
Student coffee 
drinkers                 
(21, 25.9, 66.7) 
Sham coffee 1. Arousal suggestions: a. Told it was caffeine; b. Told it 
was not caffeine   
2. Association: a. Given in a juice solution; b. Given in a 
coffee solution  
None 
Mrna and 
Skrivanek 
(1985)  
a,b,e 
W Healthy 
volunteers   
(21, 17.0, 47.6) 
Sham arousal 
drug 
1. Arousal suggestions: a. Told it was a new doping drug 
undetectable by anti-doping tests; b. Told it was to relax 
pre-restart states  
Prior placebo 
response 
Neukirch and 
Colagiuri 
(2014) 
 a,e 
RCT  
(B)  
Students with 
sleep difficulty      
(91, 21.3, 33.0) 
Sham sleep 
medication 
1. Symptom suggestions: a. Warned about an 
increase/decrease in appetite and received placebo 
treatment (24); b. Warned about the side effect but 
received no treatment (23); c. Not warned about the side 
effects and received placebo treatment (22); d. Not 
warned about the side effects and received no treatment 
(22) 
None 
Nevelsteen et 
al. (2007) 
e 
RCT  
(B)  
Healthy males       
(59, 48.4, 100.0) 
Sham 
magnetic 
field 
1. Peformance suggestions: a. Told magnetic fields 
enhance cognitive performance (15); b. Told magnetic 
fields impair cognitive performance (15); c. Told 
magnetic fields have no effect on cognitive performance 
(14); d. Not exposed to sham magnetic field and received 
no information (15) 
State-trait anxiety, 
Depression, Positive 
and Negative affect, 
Sensitivity to anxiety, 
Vigilance, Comfort 
under helmet 
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Ossege et al. 
(2005) 
RCT 
(B) 
Healthy 
volunteers  
(60, 27.6, 40.0) 
Placebo drug 1. Likelihood suggestions: a. Misleading information that 
is was an active medication (30); b. 50% chance that it 
was a placebo or active medication (30) 
None 
Papoiu et al. 
(2011) 
e 
RCT 
(W)    
Healthy 
volunteers and 
patients with 
atopic dermatitis   
(25, U/K, 44.0) 
Sham 
histamine  
1. Social observation: a. Watched a 5 minute video of 
people scratching their left forearm; b. Watched a 5 
minute video of the same persons in the scratching video 
but sitting idle. 
Gender 
Penick and 
Fisher (1965)  
a,b,c,e 
W Healthy medical 
students                 
(14, U/K, U/K) 
Sham arousal 
drug  
1. Arousal suggestions: a. Told they would receive a 
stimulant drug; b. Told they would receive a sedative 
drug  
None 
Pennebaker 
and Skelton 
(1981) 
e 
RCT  
(B) 
Students                
(38, U/K, 31.6) 
Ultrasonic 
noise 
1. Symptom suggestions: a. Told it would increase skin 
temperature (13); b. Told it would decrease skin 
temperature (12); c. Told it would have no effect on skin 
temperature (13) 
None 
Put et al. 
(2004) 
a,b,c,e 
W Asthma patients 
(32, 40.0, 50.0) 
Sham inhaler 1. Symptom suggestions: a. Told it would have no effect 
on breathing; b. Told it was a bronchoconstrictor; c. Told 
it was a bronchodilator 
Negative affect, 
Social desirability 
Read and 
Bohr (2014)  
a,b,c,e 
Non 
RCT  
(B) 
Volunteers 
without 
photosensitive 
epilepsy                 
(177, 25.3, U/K) 
Sham 3D TV 1. Symptom suggestions: a. Told it was 3D and wore 
passive 3D glasses (22); b. Told it was 3D and wore 
active no shuttering 3D glasses (33); c. Told it was 2D 
and did not wear glasses (122) 
Gender 
Schneider et 
al. (2006)  
c,e 
RCT 
(B) 
Healthy Adults      
(45, 31.0, 22.2) 
Sham 
coffee 
1. Arousal suggestions: a. Told they were to consume 
decaffeinated coffee (15); b. Told they were to consume 
regular coffee (15); c. Informed they would receive no 
beverage and no instructions (15) 
None 
Schweiger and 
Parducci 
(1981) 
e 
RCT  
(B) 
Students                
(34, U/K, 52.9) 
Sham electric 
current 
1. Symptom suggestions: a. Told a low current would be 
delivered, too mild to be felt but had produced mild 
headaches in the past (17); b. Told current would be too 
weak to be felt, but some people develop mild headaches 
None 
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as a side effect (17) 
Slanska et al. 
(1974)  
a,e  
Non 
RCT 
(B) 
Medical 
students     
(33, U/K, U/K) 
Salt solution 1. Arousal suggestions: a. Told it was a stimulant (17); b. 
Told it was a sedative (16)  
Stability ± instability, 
Activity ± passivity, 
Submissive-
dominance,                 
Rationality-
sensuousness, 
Introversion-
extraversion 
Stegen et al. 
(1998) 
e 
RCT 
(W) 
Healthy 
psychology 
students  
(72, U/K, 48.6) 
Breathing 
trial with 
room air 
1. Conditioning: a. Room air breathing trial before 7.5% 
CO2 challenge; b. Room air breathing trial after 7.5% 
CO2 challenge 
Negative affect 
Szemerszky et 
al. (2010) 
a,b,c,e 
W Healthy students   
(40, 22.8, 27.5) 
Sham EMF 1. Perceived dose: a. Told it would be weak; b. Told it 
would be strong 
Gender, Expectations, 
IEI-EMF scores, State 
anxiety, Dispositional 
optimism, 
Somatisation, 
Somatosensory 
amplification, 
Motivation 
Tippens et al. 
(2014) 
e 
RCT  
(B) 
Obese adults         
(79, 49.4, 10.4) 
Sham weight 
loss supple-
ment 
1. Likelihood suggestions: a. Told they would be given 
an active weight loss supplement (27); b. Told they 
would be randomly assigned to either the active or 
placebo supplement (28); c. Only received lifestyle 
education (24) 
None 
Van den 
Bergh et al. 
(1999) 
a,e 
Non 
RCT  
(B+W) 
Healthy students 
(64, U/K, 25.0) 
Odours 1. Odour: a. Foul smelling ammonia; b. Foul smelling 
butyric acid 
2. Conditioning: a. Ammonia paired with CO2 breathing 
task, butyric acid paired with room air breathing task 
(32); b. Ammonia paired with room air breathing task, 
None 
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butyric acid paired with CO2 breathing task (32) 
Van den 
Bergh et al. 
(1995) 
a,e 
Non 
RCT  
(B+W) 
Healthy students 
(28, U/K, 50.0) 
Odours 1. Odour: a. Foul smelling ammonia; b. Pleasant smelling 
niaouli 
2. Conditioning : a. Ammonia paired with CO2 breathing 
task, Niaouli paired with room air breathing task (14); b. 
Ammonia paired with room air breathing task, Niaouli 
paired with CO2 breathing task (14) 
Negative affect  
Van den 
Bergh et al. 
(1997) 
a,e 
Non 
RCT  
(B+W) 
Psychosomatic 
patients  
(28, 36.0, 50.0) 
Odours 1. Odour: a. Foul smelling ammonia; b. Pleasant smelling 
niaouli 
2. Conditioning : a. Ammonia paired with CO2 breathing 
task, Niaouli paired with room air breathing task (14); b. 
Ammonia paired with room air breathing task, Niaouli 
paired with CO2 breathing task (14) 
3. Generalisation: a. New foul smelling odour Ichytol; b. 
New pleasant smelling odour Rose 
Gender, State and trait 
anxiety, Blunting 
behaviour 
Van den 
Bergh et al. 
(1998) 
e 
RCT  
(B+W) 
Healthy adults 
(56, 42.5, 50.0) 
Odours 1. Odour: a. Foul smelling ammonia; b. Pleasant smelling 
niaouli 
2. Self-awareness: a. Told to count lower tones and 
disregard higher tones (28); b. Told to ignore tones (28) 
3. Conditioning: a. Ammonia paired with CO2 breathing 
task, Niaouli paired with room air breathing task (28); b. 
Ammonia paired with room air breathing task, Niaouli 
paired with CO2 breathing task (28) 
4. Generalisation: a. New foul smelling odour Ichytol; b. 
New pleasant smelling odour Rose 
Gender 
Van Diest et 
al. (2006) 
e 
RCT 
(B+W) 
Students 
(28, U/K, 21.4) 
Odours 1. Odour: a. Foul smelling ammonia; b. Foul smelling 
acetic acid 
2. Conditioning : a. Ammonia paired with hypocapnic 
over breathing trial, acetic acid paired with normocapnic 
over breathing trial (13); b. Ammonia paired with 
normocapnic over breathing tria, acetic acid paired with 
None 
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hypocapnic over breathing trial (15) 
3. Type of breathing: a. Test odours given with 
normocapnic breathing trial (U/K); b. Test odours given 
with spontaneous breathing (U/K) 
Walach and 
Schneider 
(2009) Exp 1      
RCT 
(B) 
Healthy adult 
coffee drinkers      
(60, 32.3, 23.3) 
Sham coffee 1. Likelihood suggestions: a. Told it was caffeine (15); b. 
Told it could be placebo or caffeine (15); c. Told it could 
be placebo or caffeine (15); d. Received no beverage (15) 
Expectations 
Walach and 
Schneider 
(2009) Exp 2      
RCT 
(B) 
Healthy adults 
coffee drinkers      
(30, 29.9, 33.3) 
Sham coffee 1. Arousal suggestions: a. Told it was caffeine (15); b. 
Received no beverage (15) 
Expectations 
Walach et al. 
(2001)  
 
RCT 
(B) 
Coffee drinkers     
(157, 28.1, 34.0) 
Sham 
coffee 
1. Likelihood suggestions: a. Told they would receive a 
placebo (41); b. Told they would receive coffee (39); c. 
Told they may receive real coffee or decaffeinated coffee 
(39); d. No substance or instruction given (38) 
2. Experimenter expectations: a. Experimenter told the 
physiological effects from a caffeine placebo are real 
(proplacebo) (U/K); b. Experimenter told the effects of 
caffeine placebos are just due to artefacts (antiplacebo) 
(U/K)                                     
Expectations 
Walach et al. 
(2002)  
 
RCT 
(B) 
Coffee drinkers     
(159, 25.5, 58.0) 
Sham 
coffee 
1. Symptom suggestions: a. Received an information 
leaflet describing the pharmacological effects of caffeine 
(U/K); b. Received no further information (U/K) 
2. Likelihood suggestions: a. Told they would receive a 
placebo (39); b. Told they would receive coffee (40); c. 
Told they may receive real coffee or decaffeinated coffee 
(40); d. No substance or instruction given (40)                     
None 
Winters et al. 
(2001) Exp 1 
a,e 
Non 
RCT  
(B) 
Psychology 
students  
(50, U/K,U/K) 
Ammonia 1. Conditioning : a. Odour + CO2 trials and room air 
trials (10); b. Odour trials and CO2 trials (10); c. Odour 
trials, CO2 trials, odour + CO2 trials, room air trials (10); 
d. odour trials, room air trials (10); e. CO2 trials, room 
air trials (10) 
None 
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Note: RCT = Randomised Controlled Trial, Non RCT = Non randomised controlled trial, B = Between subjects design, W = Within subjects 
design, U/K= Unknown, italicised = not directly given but has been extrapolated from the available data, rTMS = Repetitive Transcranial 
Magnetic Stimulation, EMF = Electromagnetic Field, tsp = Teaspoon, IEI-EMF = Idiopathic environmental intolerance attributed to 
electromagnetic fields, CO2 = Carbon dioxide, O2 = Oxygen, ns = non-significant, a = high risk random sequence generation bias, b = high risk 
Winters et al. 
(2001) Exp 2 
a,e 
Non 
RCT  
(B) 
18-30 year olds 
(40, U/K,U/K) 
Odours 1. Odour: a. Foul smelling ammonia (20); b. Pleasant 
smelling niaouli (20) 
2. Conditioning : a. Odour + CO2 trials and room air 
trials (20); b. Odour trials and CO2 trials (20) 
None 
Winters et al. 
(2003) 
e 
 
Non 
RCT 
(B+W) 
18-30 year olds 
(32, U/K,15.6) 
Odours 1. Odour: a. Foul smelling ammonia; b. Pleasant smelling 
niaouli 
2. Conditioning : a. Ammonia paired with CO2 breathing 
task, Niaouli paired with room air breathing task (16); b. 
Ammonia paired with room air breathing task, Niaouli 
paired with CO2 breathing task (16) 
3. Verbal suggestions of symptoms: a. Given leaflet 
describing widespread chemical pollution of the 
environment is a potential cause of multiple chemical 
sensitivity (16); b. No information given (16) 
None 
Wise et al. 
(2009) 
c 
RCT 
(B) 
Patients with 
poor asthma 
control 
(241, 39.0, 29.5) 
Sham asthma 
drug 
a. Emphasized benefit of treatment and described 
potential side effects (121) 
b. Expressed uncertainty about improvement following 
treatment and did not describe potential side effects (120)  
None 
Witthöft and 
Rubin (2013) 
RCT  
(B) 
Adult English 
speakers                
(147, 29.8, 32.7) 
Sham EMF 1. Symptom suggestions: a. Watched a documentary 
concerning the potential adverse health effects of Wi-Fi 
(76);  b. Watched a BBC News report concerning the 
security of the internet and mobile phone data (71) 
State anxiety, Age, 
Gender, Level of 
education, Personality 
Zimmermann-
Viehoff et al. 
(2013)  
b,e 
RCT  
(B) 
Healthy 
caucasians    
(92, 24.5, 41.3) 
Sham arousal 
oral spray 
1. Symptom suggestions: a. Told it contained a drug to 
increase BP (33); b. Told it contained a drug to decrease 
BP (29); c. Told it was a placebo (30) 
None 
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allocation concealment bias, c = high risk blinding of participants and personnel bias, e = did not mention an a priori sample size calculation, Not 
assessed = did not assess interactions with another risk factor, N/A = no other risk factors assessed 
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Table 2. Summary of the methods used in prospective studies 
Reference and quality Study 
design 
Population                 
(N, Mean age, %Male) 
Inert exposure Baseline risk factor(s) 
Bogaerts et al. (2010) 
e 
P Female patients with 
medically unexplained 
dyspnea and healthy controls 
(58, U/K, 0.0) 
Breathing trial with 
room air 
State anxiety, Negative affect, Clinical condition 
Casper et al. (2001) 
e 
P Nonpsychotic major 
depressive patients                
 (876, U/K, 42.8) 
Sham fluoxetine 
treatment  
Gender, Depression severity 
Danker-Hopfe et al. 
(2010) 
 
P Villages in Germany with 
weak RF-EMF sources              
(397, U/K, 49.1) 
Sham EMF Bad sleep quality, General fear/anxiety towards risks of 
RF-EMF, Fear/anxiety towards base station, 
Preoccupation with EMF, Visibility of the base station 
Davis et al. (1995) 
a,d,e 
P Healthy Adults          
(27, U/K, 55.6) 
Sham anti-
depressant pill 
Neuroticism, Somatosensory amplification     
de la Cruz et al. 
(2010) 
e 
P Patients with cancer related 
fatigue 
(105, U/K, 40.0) 
Sham treatment Anxiety, Nausea, Sleep, General health, Well-being, 
Cognitive status, Age, Education level 
De Peuter et al. 
(2007) 
e 
P Asthma patients 
(30, 38.0, 26.7) 
Sham histamine 
inhalation 
Negative affect 
Drici et al. (1995) 
b,e 
P Healthy volunteers             
(52, 23.5, 50.0) 
Sham paracetamol 
eye drop  
Employment, Type A Personality, Type B Personality  
Fillmore and Vogel-
Sprott (1992) 
e 
P Male students 
(56, U/K, 100.0) 
Sham coffee Symptom expectations 
Goetz et al. (2008) 
e 
P Parkinson's patients with 
dyskinesia            
(484, U/K, U/K) 
Sham medication Age, Gender, Dyskinesia severity, UPDRS motor 
score, Daily L-dopa dose, Dyskinesia duration, 
Adverse events, Severity of adverse events, 
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Geographical site of enrolment, Study  (1 or 2) 
Köteles and Babulka 
(2014) 
a,d,e 
P Adult volunteers      
(33, 37.7,15.2) 
3 types of Essential 
oils (Randomised to 
1) 
Expectations, Pleasantness of odour 
Liccardi et al. (2004) 
b,e 
P Patients with ADRs                    
(600, 42.0, 30.3) 
Sham allergen pill  Gender, Hospital centre 
Link et al. (2006) 
a,b,c,d,e 
P Students                  
(36, 22.7, 44.0) 
Sham herbal 
supplement 
Expectations, State anxiety, Social desirability 
Lombardi et al. 
(2008) 
a,d,e 
P Patients with ADRs                    
(435, 39.7, 32.0) 
Sham allergen pill  Gender, Age, Atopic status, Severity of previous 
reaction, Type of previous reaction 
Molcan et al. (1982) 
b,e 
P Medical students    
(48, U/K, 52.1) 
Sham arousal pill Expectations, State anxiety, Trait anxiety 
Stegen et al. (2000) 
a,b,d,e 
P Healthy psychology students 
(44, U/K, 27.3) 
Breathing trial with 
room air 
Negative affect, Social desirability 
Strohle (2000) 
e 
P Healthy adults and patients 
with panic disorder                     
(U/K, 33.5, 56.6) 
Sham panic disorder 
trigger  
Gender, Clinical condition 
Sullivan et al. (2008) 
c,e 
P Patients with neuropathic 
pain      
(24, 54.7, 62.5) 
Sham cream 
treatment 
Pain catastrophising 
Vase et al. (2013) 
e 
P Patient with pain due to tooth 
removal                        
(U/K, 25.5, 47.5) 
Sham acupuncture Expectations 
Wendt et al. (2014) 
e 
P Healthy males          
(24, 25.0, 100.0)      
Sham immuno-
suppressive capsule 
Genes 
Note: RCT = Randomised Controlled Trial, Non RCT = Non randomised controlled trial, P = Prospective design, B = Between subjects design, 
W = Within subjects design, U/K= Unknown, italicised = not directly given but has been extrapolated from the available data, F = Female, M = 
Male, ns = non-significant, UPDRS = Unified Parkinson's disease rating scale, RF-EMF =  Radio frequency electromagnetic fields, EMF = 
Electromagnetic fields, a = high risk for selection bias, b = high risk for confounding factors, c = high risk for insufficient follow-up, d = high 
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risk for low generalisability, e = did not mention an a priori sample size calculation, Not assessed = did not assess interactions with another risk 
factor , N/A = no other risk factors assessed 
  
SYSTEMATIC REVIEW OF NOCEBO EFFECT RISK FACTORS 
 
 
65 
 
Supplementary Table 3. The effect of learning on symptom reporting in response to an inert exposure 
Reference 
and quality 
Study 
design 
Population 
(N, Mean age, 
%Male) 
Inert 
exposure 
Experimental conditions (n) Main effect on symptoms measured  Interaction(s) with other risk factors 
Andre-
Obadia et al. 
(2011)  
b,e 
RCT 
(W) 
Chronic 
neuropathic pain 
patients 
(45, 55.0, 37.8)      
Sham 
rTMS 
1. Prior experience: a. Sham 
rTMS before active rTMS 
(20); b. Sham rTMS after 
successful active rTMS (12); 
c. Sham rTMS after 
ineffective active rTMS (13) 
i. Mean pain intensity (c>a>b) 
"placebo sessions tended to worsen 
pain when following an unsuccessful 
rTMS" ± no statistics given 
ii. Combined pain assessment 
"Comparable results obtained" ± no 
statistics given 
No significant interactions with 
baseline pain ratings 
Bayer et al. 
(1998)  
a,e 
RCT 
(B) 
Job seekers 
(62, U/K, 82.0) 
Sham 
electrical 
shock 
1. Prior experience: a. 
Exposed to two physical pain 
induction procedures prior to 
sham stimulation (32); b. 
Warned of pain and received 
sham stimulation. They were 
not exposed to any prior pain 
induction (30) 
i. Subjects reporting pain (ns) 
ii. Mean maximal pain rating (ns) 
iii. Subjects reporting pain over 
analgesic threshold (ns) 
iv. Pain intensity over time (ns)              
Prior experience x Dose          
i-iii. Not assessed 
iv. Increased  with increasing stimulator 
settings for those in condition a (p<.01), 
ns for those in condition b  
Dalton 
(1999) 
e 
RCT 
(B) 
Healthy 
volunteers 
(180, 31.7, 49.4) 
Odours 1. Odours: a. Pleasant 
smelling methyl salicylate 
(60); b. neutral smelling 
isobornyl acetate (60); c. Foul 
smelling butanol (60) 
i. Symptom reports (ns) Odours x Verbal symptom suggestions 
L³+LJKHVWIRUWKRVHH[SRVHGWREXWDQRO
following negative suggestions, lowest 
for those exposed to methyl salicylate 
IROORZLQJSRVLWLYHVXJJHVWLRQV´ 
No other interactions assessed 
De Peuter et 
al. (2005) 
e 
RCT 
(W) 
Asthma patients 
and healthy 
controls  
(40, 23.9, 52.5) 
Sham 
inhaler 
1. Conditioning: a. One sham 
inhaler previously paired with 
CO2 challenge; b. One sham 
inhaler previously paired with 
O2 
i. Total symptom score (a>b, p<.01) 
ii. Obstruction (ns) 
iii. Dyspnea (a>b, p<.01) 
iv. Fatigue (ns) 
v. Hyperventilation (ns) 
vi. Anxiety (ns) 
vii. Irritation (ns) 
No significant interaction with clinical 
condition 
No other interactions assessed 
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Devriese et 
al. (2000) 
a,e 
Non 
RCT 
(B+W) 
Healthy students 
(56, U/K, 41.1) 
Odours 1. Odour: Within each group 
participants were exposed to 
foul smelling ammonia and 
pleasant smelling niaouli 
2. Conditioning: a. Ammonia 
paired with CO2 breathing 
task, Niaouli paired with room 
air breathing task (28); b. 
Ammonia paired with room 
air breathing task, Niaouli 
paired with CO2 breathing 
task (28) 
3. Generalisation: Within each 
group participants were 
exposed to a. a new foul 
smelling odour butyric acid; b. 
a new foul smelling odour 
acetic acid; and c. a new 
pleasant smelling odour citric 
aroma 
i. Total symptom score (1 ns; 2 ns; 3 
a>b+c, p<.001, b vs c ns) 
ii. Arousal (1 ns; 2 ns; 3 ns) 
iii. Respiratory (1 ns; 2 ns; 3 ns) 
iv. Cardiac (1 ns; 2 ns; 3ns) 
v. Tingling (1 ns; 2 ns; 3 ns) 
vi. Unclassified (1 ns; 2 ns; 3 ns) 
vii. Dummy (1 ns; 2 ns; 3 ns) 
Conditioning x Odour 
i+iii. Higher in response to odour paired 
with CO2 but only when the odour was 
ammonia (p<.05) 
ii, iv-vii. ns 
Conditioning x Odour x Negative affect 
i+iii. Higher in response to odour paired 
with CO2 but only when the odour was 
ammonia and participants had high 
negative affect (p<.05) 
ii, iv-vii. ns 
Odour x Negative affect x 
Generalisation 
i+iii. Higher in response to butyric and 
acetic acid than citric aroma when 
ammonia was paired with CO2 and 
participants had high negative affect 
(p<.05) 
iv. Higher in response to butyric acid 
than acetic acid or citric aroma when 
ammonia was paired with CO2 and 
participants had high negative affect 
(p<.05) 
ii+ v-vii. Ns 
No other interactions assessed 
Devriese et 
al. (2004) 
a,e 
Non 
RCT 
(B+W) 
Healthy students 
(53, U/K, U/K) 
Odours 1.  Odour: Within each group 
participants were exposed to 
foul smelling ammonia and 
foul smelling butyric acid 
2.  Conditioning: a. Ammonia 
paired with CO2 breathing 
task, butyric acid paired with 
room air breathing task (28); 
b. Ammonia paired with room 
air breathing task, butyric acid 
paired with CO2 breathing 
task (25) 
i. Total symptom score (1 ns; 2 ns) 
ii. Arousal (1 ns; 2 ns) 
iii. Respiratory (1 ns; 2 ns) 
iv. Cardiac (1 ns; 2 ns) 
v. Tingling (1 ns; 2 ns) 
vi. Unclassified (1 ns; 2 ns) 
vii. Dummy (1 ns; 2 ns) 
Odour x Conditioning 
i. Higher in response to butyric acid 
than ammonia when butyric acid paired 
with room air (p<.01) 
ii-vii. ns 
Perceived cue odour x Odour 
i. Higher to butyric acid than ammonia 
when butyric acid was thought to have 
been paired with CO2 (p<.05) 
ii-vii. ns 
No other interactions assessed 
SYSTEMATIC REVIEW OF NOCEBO EFFECT RISK FACTORS 
 
 
67 
 
Devriese et 
al. (2006) 
RCT 
(B+W) 
Psychology 
students 
(40, U/K, 0.0) 
Odour 1.  Odour: Within each group 
participants were exposed to 
foul smelling ammonia and 
foul smelling acetic acid 
2.  Conditioning: a. Ammonia 
paired with CO2 breathing 
task, acetic acid paired with 
room air breathing task (20); 
b. Ammonia paired with room 
air breathing task, acetic acid 
paired with CO2 breathing 
task (20) 
i. Total symptom score (1 ns; 2 
higher for the odour paired with CO2 
than the odour paired with room air, 
p<.05) 
ii. Arousal (1 ns; 2 ns) 
iii. Respiratory (1 ns; 2 ns) 
iv. Cardiac (1 ns; 2 ns) 
v. Tingling (1 ns; 2 ns) 
vi. Unclassified (1 ns; 2 ns) 
vii. Dummy (1 ns; 2 ns) 
Not assessed 
Dinnerstein 
and Halm 
(1970) 
c,e 
RCT 
(B) 
Male students 
(80, U/K, 100.0) 
Sham 
arousal 
liquid 
1. Prior experience: a. 
Received aspirin prior to sham 
(40); b. Received lactose prior 
to sham (40)                                 
i. Friendly (ns) 
ii. Aggressive (ns) 
iii. Sleepy (ns) 
iv. Dizzy (ns) 
v. Unhappy (ns) 
vi. Clear thinking (ns) 
Prior experience x Arousal suggestion 
i. Lower in condition a than condition b 
under energiser suggestion, reverse 
under tranquiliser suggestion (p<.05) 
ii-iv. ns 
v+vi. Higher in condition a than 
condition b under energiser suggestion, 
reverse under tranquiliser suggestion 
(ps<.05)                                       
Flaten and 
Blumenthal 
(1999) 
e 
RCT 
(W) 
Healthy coffee 
drinkers 
(21, 24.8, 61.9) 
Decaffeina
ted 
solution 
1. Association: a. Given in an 
orange juice solution; b. Given 
in a coffee solution 
i. Stress score (ns) 
ii. Arousal score (b>a, p<.05) 
iii. Alertness score (b>a, p<.05) 
N/A 
Lorber et al. 
(2007)  
e 
RCT 
(B) 
Students 
without upper 
respiratory 
conditions 
(86, U/K, 40.7) 
Sham 
environme
ntal toxin  
1. Social observation: a. Told 
inhaled substance has been 
reported to produce symptoms 
and observed a female 
confederate inhale and display 
symptoms (U/K) 
b. As above but no 
observation of confederate 
(U/K) 
c. Did not inhale the substance 
and observed a female 
confederate inhale and display 
i. Specified verbal symptom ratings: 
headache, nausea, itchy skin, 
drowsiness (ns) 
ii. Other verbal symptom ratings:  
watery eyes, scratchy throat, chest 
tightness, and breathing difficulty 
(ns) 
Observation x Gender 
i. Higher in observation compared to no 
observation conditions when 
participants are female (p<.05) 
ii. ns 
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symptoms (U/K) 
d. As above but no 
observation of confederate 
(U/K) 
Mazzoni et 
al. (2010) 
e 
RCT 
(B) 
Healthy students 
(120, 20.7, 50.0) 
Sham 
environme
ntal toxin  
1. Social observation: a. 
Observed a male/female 
confederate inhale the 
substance and display 
symptoms (60) 
b. Did not observe a 
male/female confederate 
inhale the substance and 
display symptoms (60) 
i. Specified verbal symptom ratings: 
headache, nausea, itchy skin, 
drowsiness (a>b, p<.001) 
ii. Other verbal symptom ratings:  
watery eyes, scratchy throat, chest 
tightness, and breathing difficulty 
(ns)  
Not assessed 
Meulders et 
al. (2010) 
a,e 
Non 
RCT 
(B+W) 
Healthy adults 
(58, 22.0, 48.3) 
Odours 1. Odour: Within each group 
participants were exposed to 
foul smelling ammonia and 
foul smelling butyric acid 
2.  Conditioning: a. Ammonia 
paired with CO2 breathing 
task, butyric acid paired with 
room air breathing task (29); 
b. Ammonia paired with room 
air breathing task, butyric acid 
paired with CO2 breathing 
task (29) 
 
i. Total symptom score (1 ns; 2 ns) 
ii. Arousal (1 ns; 2 ns) 
iii. Respiratory (1 ns; 2 ns) 
iv. Cardiac (1 ns; 2 ns) 
v. Tingling (1 ns; 2 ns) 
vi. Unclassified (1 ns; 2 ns) 
vii. Dummy (1 ns; 2 ns) 
Conditioning x Ability to predict 
i. Higher in response to odours which 
had been paired with CO2 compared to 
room air when participants were able to 
predict which odour had caused the 
most symptoms (p<.05) 
ii-vii. ns 
Conditioning x Ability to predict x 
Odour 
i-iv+vii. Higher in response to butyric 
acid which had been paired with CO2 
compared to room air when participants 
were able to predict which odour had 
caused the most symptoms (i-iv, p<.01; 
vii, p<.05) 
v+vi. ns 
No other interactions assessed 
Mikalsen et 
al. (2001)  
a,b,e 
RCT 
(W) 
Student coffee 
drinkers 
(21, 25.9, 66.7) 
Sham 
coffee 
1. Association: a. Given in a 
juice solution (U/K); b. Given 
in a coffee solution (U/K)            
i. Alertness VAS score (b>a, p<.05) 
ii. Contentedness VAS score (b>a, 
p=.02) 
iii. Calmness VAS score (ns) 
Not assessed 
Papoiu et al. 
(2011) 
e 
RCT 
(W)    
Healthy 
volunteers and 
patients with 
Sham 
histamine  
1. Social Observation: a. 
Watched a 5 minute video of 
people scratching their left 
i. Average itch intensity rating (a>b 
for patients p=.027; ns for healthy 
volunteers) 
No significant interactions with gender 
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atopic dermatitis   
(25, U/K, 44.0) 
forearm 
b. Watched a 5 minute video 
of the same persons in the 
scratching video but sitting 
idle. 
ii. Scratching behaviour (a>b for 
patients p=.002; ns for healthy 
volunteers) 
Stegen et al. 
(1998) 
e 
RCT 
(W) 
Healthy 
psychology 
students  
(72, U/K, 48.6) 
Breathing 
trial with 
room air 
1. Prior experience: a. Room 
air breathing trial before 7.5% 
CO2 challenge; b. Room air 
breathing trial after 7.5% CO2 
challenge 
i. Total symptom score (ns) 
ii. General arousal (a>b, p<.001) 
iii. Respiration (a>b, p<.001) 
iv. Cardiac (ns) 
v. Tingling (ns) 
vi. Unclassified (ns) 
vii. Gastrointestinal (ns) 
viii. Dizziness (ns) 
Prior experience x Negative affect 
i+ii. Participants scoring high on 
negative affect reported more 
complaints than participants with low 
negative affect in condition a (i, 
p<.001; ii, p<.005) 
iii-viii. ns 
Van den 
Bergh et al. 
(1995) 
a,e 
Non 
RCT  
(B+W) 
Healthy students 
(28, U/K, 50.0) 
Odours 1. Odour: Within each group 
participants were exposed to 
foul smelling ammonia and 
pleasant smelling niaouli 
2. Conditioning: a. Ammonia 
paired with CO2 breathing 
task, Niaouli paired with room 
air breathing task (14); b. 
Ammonia paired with room 
air breathing task, Niaouli 
paired with CO2 breathing 
task (14) 
i. Total symptom score (1 ns; 2 ns) 
ii. Arousal (1 ns; 2 ns) 
iii. Respiratory (1 ns; 2 ns) 
iv. Cardiac (1 ns; 2 ns) 
v. Tingling (1 ns; 2 ns) 
vi. Unclassified (1 ns; 2 ns) 
Conditioning x Odour 
i-iii+vi. Higher in response to odour 
paired with CO2 but only when that 
odour was ammonia (i, p<.05; ii, 
p<.001; iii, p<.02; vi, p<.05) 
iv+v. ns 
No other interactions assessed  
Van den 
Bergh et al. 
(1997) 
a,e 
Non 
RCT  
(B+W) 
Psychosomatic 
patients  
(28, 36.0, 50.0) 
Odours 1. Odour: Within each group 
participants were exposed to 
foul smelling ammonia and 
pleasant smelling niaouli 
2. Conditioning: a. Ammonia 
paired with CO2 breathing 
task, Niaouli paired with room 
air breathing task (14); b. 
Ammonia paired with room 
air breathing task, Niaouli 
paired with CO2 breathing 
task (14) 
i. Total symptom score (1 ns; 2 
higher for odours that had been 
paired with CO2 compared to room 
air; 3 ns) 
ii. Arousal (1 ns; 2 ns; 3 ns) 
iii. Respiratory (1 ns; 2 ns; 3 ns) 
iv. Cardiac (1 ns; 2 ns; 3 ns) 
v. Tingling (1 ns; 2 ns; 3 ns) 
vi. Unclassified (1 ns; 2 ns; 3 ns) 
vii. Dummy (1 ns; 2 ns; 3 ns) 
Conditioning x Odour 
i+iii+vi. Higher for odour paired with 
CO2 but only when that odour was 
ammonia (i+iii, p<.001; vi, p<.005) 
ii+iv+v+vii. Ns 
No other interactions assessed 
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3. Generalisation: Within each 
group participants were 
exposed to a new foul 
smelling odour Ichytol and 
new pleasant smelling odour 
Rose 
Van den 
Bergh et al. 
(1998) 
e 
RCT  
(B+W) 
Healthy adults 
(56, 42.5, 50.0) 
Odours 1. Odour: Within each group 
participants were exposed to 
foul smelling ammonia and 
pleasant smelling niaouli 
2. Conditioning: a. Ammonia 
paired with CO2 breathing 
task, Niaouli paired with room 
air breathing task (28); b. 
Ammonia paired with room 
air breathing task, Niaouli 
paired with CO2 breathing 
task (28) 
3. Generalisation: Within each 
group participants were 
exposed to a new foul 
smelling odour Ichytol and 
new pleasant smelling odour 
Rose 
i. Total symptom score (1 ns; 2 ns; 3 
higher in response to ichytol than 
rose odour, p<.005) 
ii. Arousal (1 ns; 2 ns; 3 ns) 
iii. Respiratory (1 ns; 2 ns; 3 ns) 
iv. Cardiac (1 ns; 2 ns; 3 ns) 
v. Tingling (1 ns; 2 ns; 3 ns) 
vi. Unclassified (1 ns; 2 ns; 3 ns) 
vii. Dummy (1 ns; 2 ns; 3 ns) 
Conditioning x Odour x Self-awareness 
i+ii+iv+vi+vii. Higher in response to 
the odour paired with CO2 when this 
was ammonia and participants had not 
been distracted (i+ii, p<.001, iv+vi+vii, 
p<.002) 
ii+v. ns 
No other interactions assessed 
Van den 
Bergh et al. 
(1999) 
a,e 
Non 
RCT  
(B+W) 
Healthy students 
(64, U/K, 25.0) 
Odours 1.  Odour: Within each group 
participants were exposed to 
foul smelling ammonia and 
foul smelling butyric acid 
2.  Conditioning: a. Ammonia 
paired with CO2 breathing 
task, butyric acid paired with 
room air breathing task (32); 
b. Ammonia paired with room 
air breathing task, butyric acid 
paired with CO2 breathing 
task (32) 
i. Total symptom score (1 ns; 2 
higher in response to odour paired 
with CO2 compared to room air, 
p<.001) 
ii. Arousal (1 ns; 2 ns) 
iii. Respiratory (1 ns; 2 higher in 
response to odour paired with CO2 
compared to room air, p<.001) 
iv. Cardiac (1 ns; 2 ns) 
v. Tingling (1 ns; 2 ns) 
vi. Unclassified (1 ns; 2 higher in 
response to odour paired with CO2 
compared to room air, p<.001) 
Not assessed 
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vii. Dummy (1 ns; 2 ns) 
Van Diest et 
al. (2006) 
e 
RCT 
(B+W) 
Students 
(28, U/K, 21.4) 
Odours 1. Odour: Within each group 
participants were exposed to 
foul smelling ammonia and 
foul smelling acetic acid 
2. Conditioning: a. Ammonia 
paired with hypocapnic over 
breathing trial, acetic acid 
paired with normocapnic over 
breathing trial (13); b. 
Ammonia paired with 
normocapnic over breathing 
tria, acetic acid paired with 
hypocapnic over breathing 
trial (15) 
i. Paresthesia (1 ns; 2 ns) 
ii. Cerebral (1 ns; 2 ns) 
iii. Cardiac (1 ns; 2 ns) 
iv. Gastrointestinal (1 ns; 2 ns) 
v. Respiratory (1 ns; 2 ns) 
vi. Anxiety (1 ns; 2 ns) 
vii. Neuropsychological (1 ns; 2 ns) 
viii. Unclassified (1 ns; 2 ns) 
ix. Dummy (1 ns; 2 ns) 
x. Feeling unreal (1 ns; 2 higher for 
odour paired with hypocapnic 
compared to normocapnic over 
breathing) 
Not assessed 
Winters et 
al. (2001) 
Exp 1 
a,e 
Non 
RCT  
(B) 
Psychology 
students  
(50, U/K,U/K) 
Ammonia 1. Conditioning: a. Odour + 
CO2 trials and room air trials 
(10); b. Odour trials and CO2 
trials (10); c. Odour trials, 
CO2 trials, odour + CO2 
trials, room air trials (10); d. 
odour trials, room air trials 
(10); e. CO2 trials, room air 
trials (10) 
i. Symptom reports (ns) N/A 
Winters et 
al. (2001) 
Exp 2 
a,e 
Non 
RCT  
(B) 
18-30 year olds 
(40, U/K,U/K) 
Odour 1. Odour: a. Foul smelling 
ammonia (20); b. Pleasant 
smelling niaouli (20) 
2. Conditioning: a. Odour + 
CO2 trials and room air trials 
(20); b. Odour trials and CO2 
trials (20) 
i. Symptom reports (1 ns; 2 ns) Not assessed 
Winters et 
al. (2003) 
a,e 
Non 
RCT 
(B+W) 
18-30 year olds 
(32, U/K,15.6) 
Odour 1. Odour: Within each group 
participants were exposed to 
foul smelling ammonia and 
pleasant smelling niaouli  
2. Conditioning: a. Ammonia 
paired with CO2 breathing 
i. Total symptom score (1 ns; 2 
higher in response to odour paired 
with CO2 compared to room air, 
p<.05) 
ii. Arousal (1 ns; 2 ns) 
iii. Respiratory (1 ns; 2 ns) 
Conditioning x Odour 
i. Higher in response to the odour 
paired with CO2 when this was 
ammonia (p<.05) 
ii-vii. ns 
Conditioning x Verbal symptom 
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task, Niaouli paired with room 
air breathing task (16); b. 
Ammonia paired with room 
air breathing task, Niaouli 
paired with CO2 breathing 
task (16) 
 
 
iv. Cardiac (1 ns; 2 ns) 
v. Tingling (1 ns; 2 ns) 
vi. Unclassified (1 ns; 2 ns) 
vii. Dummy (1 ns; 2 ns) 
suggestions 
i+iii+iv+vi. Higher following odour 
which was paired with CO2 when given 
symptom suggestions (i, p<.01; 
iii+iv+vi, p<.05) 
ii+v+vii. ns 
No other interactions assessed 
 
Note: RCT = Randomised Controlled Trial, B = Between subjects design, W = Within subjects design, U/K= Unknown, ns = non-significant, italicised = not directly given 
but has been extrapolated from the available data, rTMS = Repetitive Transcranial Magnetic Stimulation, CO2 = Carbon dioxed, O2 = Oxygen, a = high risk random 
sequence generation bias, b = high risk allocation concealment bias, c = high risk blinding of participants and personnel bias, e = did not mention an a priori sample size 
calculation , Not assessed = did not assess interactions with another risk factor 
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Supplementary Table 4. The effect of perceived dose manipulation on symptom reporting in response to an inert exposure 
Reference 
and quality 
Study 
design 
Population 
(N, Mean age, 
%Male) 
Inert 
exposure 
Experimental conditions 
(n) 
Main effect on symptoms measured  Interaction(s) with other risk factors 
Bayer et al. 
(1991) 
e 
RCT 
(B+W) 
Unemployed Men 
(100, U/K, 100.0) 
Sham 
electrical 
shock 
a. Within each group the 
stimulator setting 
increased from 0 to 80 mA 
i. Mean pain ratings (increased with 
greater sham stimulation, p<.001) 
No significant interactions with symptom 
suggestion 
Bayer et al. 
(1998)  
a,e 
RCT 
(B+W) 
Job seekers 
(62, U/K, 82.0) 
Sham 
electrical 
shock 
a. Within each group the 
stimulator setting 
increased in steps of 10 
every 5 minutes till it 
reached 50 
i. Number of subjects reporting pain 
(ns) 
ii. Mean maximal pain rating (ns) 
iii. Subjects reporting pain over 
analgesic threshold (ns) 
iv. Pain intensity rating over time 
(Increased, difference between 
stimulator settings, p<.01) 
Perceived dose x Prior experience          
i-iii.Not assessed 
iv. Increased with increasing stimulator 
settings for those who experienced prior 
pain (p<.01), ns for those with no prior pain  
Flaten et al. 
(2003)  
a,b,e 
W Coffee drinkers 
(20, U/K, 50.0) 
Sham 
coffee 
a. Participants were first 
given one cup and then a 
second 
i. Alertness, contentedness, 
calmness, arousal, and stress VAS 
scores (ns) 
Not assessed 
Jensen and 
Karoly 
(1991) 
e 
RCT 
(B+W)     
Students 
(86, U/K, 45.3) 
Sham 
sedative 
pill 
a. Suggestions of a high 
dose or low dose were 
counterbalanced across 
each group 
i. General placebo response rating 
(ns) 
ii. Adjective symptom checklist 
score (ns) 
No significant interactions with social 
desirability or gender 
Kirsch and 
Weixel 
(1988) 
e 
RCT 
(B)  
Student coffee 
drinkers 
(U/K, 19.3, 31.0) 
Sham 
coffee 
a. 1 tsp (U/K) 
b. 2 tsps (U/K) 
c. 3 tsps (U/K) 
d. 5 tsps (U/K) 
e. 8 tsps (U/K)                       
i. Mean change in alertness (ns) 
ii. Mean change in relaxation (ns) 
iii. Mean change in tension                 
("significant linear increase in 
tension as a function of dose", p<.03) 
Perceived dose x Likelihood suggestion          
i+iii. Increased with increasing dose in the 
deceptive group, decreased in the double-
blind group (i, p<.02; iii, p<.04)                       
ii. ns                                         
Szemerszky 
et al. (2010) 
a,b,c,e 
W Healthy students 
(40, 22.8, 27.5) 
Sham 
EMF 
a. Told it would be weak 
b. Told it would be strong 
i. Overall symptom score (b>a, 
p<.001)  
Not assessed 
Note: RCT = Randomised Controlled Trial, B = Between subjects design, W = Within subjects design, U/K= Unknown, ns = non-significant, EMF = Electromagnetic Field, 
tsp = teaspoon, italicised = not directly given but has been extrapolated from the available data, a = high risk random sequence generation bias, b = high risk allocation 
concealment bias, c = high risk blinding of participants and personnel bias, e = did not mention an a priori sample size calculation, Not assessed = did not assess interactions 
with another risk factor 
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Supplementary Table 5. The effect of self-awareness manipulation on symptom reporting in response to an inert exposure 
Reference 
and quality 
Study 
design 
Population 
(N, Mean age, 
%Male) 
Inert 
exposure 
Experimental conditions (n) Main effect on symptoms 
measured  
Interaction(s) with other risk factors 
Geers, 
Helfer, et 
al. (2005) 
e 
RCT 
(B)  
Healthy  students 
(54, 21.0, 29.6)  
Sham 
over-the-
counter pill 
a. Told to attend to any 
symptoms experienced (27) 
b. Not given any such 
instructions (27) 
i. Affect questionnaire - 
Anxiety, restlessness, relaxed, 
irritable, and perspiration (ns) 
No significant interactions with age, gender, 
likelihood suggestion or optimism     
Geers et al. 
(2006) 
e 
RCT 
(B)  
Healthy students 
(54, U/K, 31.5) 
Sham 
over-the-
counter pill 
a. Told to closely monitor 
feelings/bodily sensations (27) 
b. Not given any such 
instructions (27)  
i.  Overall placebo symptom 
index: anxiety, nausea, pleasant 
feelings, perspiration, and 
perceived pill effect (ns) 
Self-awareness x Likelihood suggestion            
i. Higher in condition a participants with 
deceptive suggestions than condition a 
participants with control suggestions (p<.01) 
and condition a participants with double-
blind suggestions (p=.02). In addition it is 
higher in condition a participants with  
deceptive suggestions than condition b 
participants with deceptive suggestions 
(p=.02) 
Gibbons et 
al. (1979)  
a,e 
RCT 
(B)  
Female students 
(38, U/K, 0.0) 
Sham drug  a. Mirror was facing 
participants (19) 
b. Mirror was not facing 
participants (19) 
i. Perceived arousal (b>a, 
p<.01) 
ii. Salient symptom checklist 
(ns) 
iii. Non salient symptom 
checklist (ns)                              
Self-awareness x Symptom suggestion   
i +iii. ns                                         
ii. Lower in condition a than condition b 
when participants were misinformed (p<.03)     
 
Van den 
Bergh et al. 
(1998) 
e 
RCT  
(B+W) 
Healthy adults 
(56, 42.5, 50.0) 
Odours a. Told to count lower tones 
and disregard higher tones 
(28) 
b. Told to ignore tones (28) 
i. Total symptom score (ns) 
ii. Arousal (ns) 
iii. Respiratory (ns) 
iv. Cardiac (ns) 
v. Tingling (ns) 
vi. Unclassified (ns) 
vii. Dummy (ns) 
Self-awareness x Conditioning 
i+ii+iv+vi+vii. Higher in response to the 
odour paired with CO2 when this was 
ammonia and participants were in condition 
b (i+ii, p<.001, iv+vi+vii, p<.002) 
ii+v. ns 
No other interactions assessed 
Note: RCT = Randomised Controlled Trial, B = Between subjects design, U/K= Unknown, ns = non-significant,  CO2 = Carbon dioxide, a = high risk random sequence 
generation bias, e = did not mention an a priori sample size calculation 
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Supplementary Table 6. The effect of type of administration manipulation on symptom reporting in response to an inert exposure 
Reference 
and quality 
Study 
design 
Population 
(N, Mean age, %Male) 
Inert exposure Experimental conditions (n) Main effect on symptoms measured  Interaction(s) with 
other risk factors 
Goldman et 
al. (1965) 
a,b,e 
Non 
RCT 
(B) 
Male veterans with 
schizophrenia 
(64, 44.0, 100.0) 
Sham arousal 
treatment  
a. Received sugar pill (32) 
b. Received saline injection (32) 
i. Reported symptoms identified 
through interviews (ns) 
ii. Reported drug effect identified 
through interviews (ns) 
iii. Ward activity (ns) 
Not assessed 
Kaptchuk et 
al. (2006) 
 
RCT 
(B) 
  
Adults with distal pain 
in the arms 
(266, 36.7, 45.9) 
Sham treatment  a. Received sham acupuncture (133) 
b. Received placebo pill (133) 
i. Frequency of one or more side 
effects reported (ns) 
N/A 
Note: RCT = Randomised Controlled Trial, Non RCT = Non-randomised controlled trial B = Between subjects design, ns = non-significant, a = high risk random sequence 
generation bias, b = high risk allocation concealment bias, e = did not mention an a priori sample size calculation, Not assessed = did not assess interactions with another risk 
factor, N/A = no other risk factors assessed  
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Supplementary Table 7. The effect of verbal suggestions on performance on symptom reporting in response to an inert exposure 
Reference 
and quality 
Study 
design 
Population 
(N, Mean age, %Male) 
Inert 
exposure 
Experimental conditions (n) Main effect on symptoms measured  Interaction(s) with 
other risk factors 
Harrell and 
Juliano 
(2009)  
c 
RCT 
(B)  
Adult non-smoking 
coffee consumers 
(30, 22.6, 22.0) 
Sham 
coffee 
a. Told caffeine enhances performance (15) 
b. Told caffeine impairs performance (15) 
i. Sum of ten self-reported symptoms 
(ns) 
ii. Profile of mood states score (ns)              
N/A  
Harrell and 
Juliano 
(2012) 
c,e 
RCT 
(B)  
Adult smokers 
(43, 28.7, 67.4) 
Sham 
cigarette 
a. Told cigarette enhances performance (20) 
b. Told cigarette impairs performance (23) 
i. Cigarette evaluation scale - cravings 
score (b>a, p=.02) 
No significant 
interaction with 
gender                       
Nevelsteen 
et al. (2007) 
e 
RCT 
(B)  
Healthy males 
(59, 48.4, 100.0) 
Sham 
magnetic 
field 
a. Told magnetic fields enhance cognitive 
performance (15) 
b. Told magnetic fields impair cognitive 
performance (15) 
c. Told magnetic fields have no effect on 
cognitive performance (14) 
d. Not exposed to sham magnetic field and 
received no information (15) 
i. Subjective vigilance feelings (ns) 
ii. Profile of mood states score (ns) 
iii. 24 Physical symptoms scale (ns) 
Not assessed 
Note: RCT = Randomised Controlled Trial, B = Between subjects design, ns = non-significant, italicised = not directly given but has been extrapolated from the available 
data, c = high risk blinding of participants and personnel bias, e = did not mention an a priori sample size calculation, Not assessed = did not assess interactions with another 
risk factor, N/A = no other risk factors assessed  
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Supplementary Table 8. The effect of verbal suggestions of likelihood on symptom reporting in response to an inert exposure 
Reference 
and quality 
Study 
design 
Population 
(N, Mean age, 
%Male) 
Inert 
exposure 
Experimental conditions (n) Main effect on symptoms 
measured  
Interaction(s) with other risk factors 
Geers et al. 
(2006) 
e 
RCT 
(B)  
Healthy students 
(54, U/K, 31.5) 
Sham over-
the-counter 
pill 
a. Told the pill had unpleasant side 
effects (18) 
b. Told they may or may not receive 
the active drug (19) 
c. Told they would ingest an inactive 
drug (17)                                                 
i.  Overall placebo symptom 
index: anxiety, nausea, 
pleasant feelings, perspiration, 
and perceived pill effect (ns) 
Likelihood suggestion x Self-awareness    
i. Higher in condition a than condition c 
(p<.01) or condition b participants 
(p=.02) when participants told to attend 
to sensations. Higher in participants 
told to attend to sensations than those 
not given such instructions when in 
condition a (p=.02) 
Geers et al. 
(2011) 
e 
RCT 
(B) 
Healthy students 
(102, 20.5, 21.6) 
Sham 
caffeine 
capsule 
a. Told it contained 250mg of 
caffeine (34) 
b. Told they may or may not be 
ingesting 250mg of caffeine (34) 
c. Not given the capsule and received 
no caffeine expectation (34) 
i. Placebo response index- 
anxious, sluggish, energized, 
calm, irritated, lazy, relaxed, 
and excited (a>b, p<.05; a>c, 
p<.01; b vs c, ns)                         
No significant interactions with gender     
Geers, 
Helfer, et 
al. (2005) 
e 
RCT 
(B)  
Healthy  
students 
(54, 21.0, 29.6)  
Sham over-
the-counter 
pill 
a. Told the pill had unpleasant side 
effects (18) 
b. Told the pill would make them feel 
either unpleasant or was an inactive 
substance (18) 
c. Told they would ingest an inactive 
pill (18)  
i. Affect questionnaire - 
Anxiety, restlessness, relaxed, 
irritable, and perspiration (ns) 
Likelihood suggestion x Optimism  
i. Higher in pessimists than optimists 
when in condition a than condition c 
(p<.05), condition a vs b, b vs c (ns)          
No significant interaction with age, 
gender or self-awareness   
Kirsch and 
Weixel 
(1988) 
e 
RCT 
(B)   
Student coffee 
drinkers 
(100, 19.3, 31.0) 
Sham coffee a. Told they would receive coffee 
(U/K) 
b. Told they may or may not receive 
caffeinated coffee (U/K) 
c. No beverage, waited for 20 
minutes (U/K)                            
i. Mean change in alertness 
(a+b>c, p<.003; a>b, U/K) 
ii. Mean change in relaxation 
(ns) 
iii. Mean change in tension 
(ns) 
Likelihood suggestion x Perceived dose 
i+iii. Increased with increasing dose in 
condition a, decreased in condition b (i, 
p<.02; iii, p<.04) 
ii. ns 
 
Ossege et 
al. (2005) 
RCT 
(B) 
Healthy 
volunteers 
(60, 27.6, 40.0) 
Placebo drug a. Told it was an active medication 
(30) 
b. Told there was a 50% chance that 
it was a placebo or active medication 
(30) 
i. Number of adverse events 
(ns) 
ii. Severity of adverse events 
(ns) 
N/A 
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Tippens et 
al. (2014) 
e 
RCT 
(B) 
Obese adults 
(79, 49.4, 10.4) 
Sham weight 
loss 
supplement 
a. Told they would be given an active 
weight loss supplement (27) 
b. Told they would be randomly 
assigned to either the active or 
placebo supplement (28) 
c. Only received lifestyle education 
(24) 
i. Number of recorded adverse 
events (a+b>c, p <.001; a vs b, 
ns) 
N/A 
Walach 
and 
Schneider 
(2009)  
Exp 1             
RCT 
(B) 
Healthy adult 
coffee drinkers 
(60, 32.3, 23.3) 
Sham coffee a. Told it was caffeine (15) 
b. Told it could be placebo or 
caffeine (15) 
c. Told it could be placebo or caffeine 
(15) 
d. Received no beverage (15) 
i. Mean change in mood (ns) 
ii. Mean change in calmness 
(ns) 
iii. Mean change in alertness 
(ns) 
Not assessed 
Walach et 
al. (2001)  
 
RCT 
(B) 
Coffee drinkers     
(157, 28.1, 34.0) 
Sham 
coffee 
a. Told they would receive a placebo 
(41) 
b. Told they would receive coffee 
(39) 
c. Told they may receive real coffee 
or decaffeinated coffee (39) 
d. No substance or instruction given 
(38)                                      
i. General wellbeing score 
(a>d, p<.0004; all other 
comparisons, ns) 
No significant interaction with 
experimenter expectations           
Walach et 
al. (2002)  
 
RCT 
(B) 
Coffee drinkers 
(159, 25.5, 58.0) 
Sham 
coffee 
a. Told they would receive a placebo 
(39) 
b. Told they would receive coffee 
(40) 
c. Told they may receive real coffee 
or decaffeinated coffee (40) 
d. No substance or instruction given 
(40)                                      
i. General wellbeing score (ns) No significant interaction with 
Symptom suggestion 
Note: RCT = Randomised Controlled Trial, B = Between subjects design, U/K= Unknown, ns = non-significant, italicised = not directly given but has been extrapolated from 
the available data, e = did not mention an a priori sample size calculation, N/A = no other risk factors assessed  
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Supplementary Table 9. The effect of verbal suggestions of arousal on symptom reporting in response to an inert exposure 
Reference 
and quality 
Study 
design 
Population 
(N, Mean Age, 
%Male) 
Inert 
exposure 
Experimental conditions (n) Main effect on symptoms 
measured  
Interaction(s) with other risk 
factors 
Angelucci 
and Pena 
(1997) 
e 
RCT 
(B) 
Student caffeine 
consumers 
(148, U/K, 23.0)    
Sham 
coffee 
a. Given coffee with no expectations (37) 
b. Given coffee with low arousal 
expectations (37) 
c. Given coffee with high arousal 
expectations (37) 
d. no coffee and no expectations (37) 
I. Stimulation/alertness (b<a+c+d, 
p<.001; all other comparisons, ns) 
ii. Anxiety/irritability (ns) 
iii. Subjective symptoms (ns) 
Not assessed 
Brodeur 
(1965) 
e 
RCT 
(B) 
Healthy senior 
students 
(45, U/K, 91.1) 
Sham 
arousal 
capsule   
a. Told it was a stimulant (15) 
b. Told it was a tranquilizer (15) 
c. No suggestion (15) 
i. Arousal score (ns) N/A 
Dinnerstein 
and Halm 
(1970) 
e 
RCT 
(B) 
Male students 
(80, U/K, 100.0) 
Sham 
arousal 
liquid 
a. Told it was an energizer (40) 
b. Told it was a tranquilizer (40)                        
i. Friendly (b<a, p<.025) 
ii. Aggressive (b<a, p<.025) 
iii. Sleepy (b>a, p<.001) 
iv. Dizzy (ns) 
v. Unhappy (ns) 
vi. Clear thinking (ns)                       
Arousal suggestion x Prior 
experience 
i. Lower after aspirin than 
lactose under condition a, 
reverse under condition b 
(p<.05) 
ii-iv. ns 
v+vi. Higher after aspirin 
than lactose under condition 
a, reverse under condition b 
(ps<.05)                                     
Flaten 
(1998) 
e 
RCT 
(B) 
Healthy students 
(48, U/K, 35.4) 
Sham 
arousal 
drink 
a. Told you will feel relaxed and sleepy (16) 
b. Told you will feel alert and a little stress 
(16) 
c. Told you will take an inactive drug (16) 
i. Subjective stress score (a<b, 
p<.05; a<c, p<.05; b vs c, ns) 
ii. Subjective arousal score (a<b, 
p<.05; all other comparisons, ns) 
N/A 
Flaten et al. 
(1999) 
e 
RCT 
(B) 
Healthy 
volunteers in 
non-health 
professions 
(34, U/K, 54.5) 
Sham 
arousal 
capsule   
a. The drug will make you feel relaxed (11) 
b. The drug will make you feel alert (12) 
c. You will receive capsules that contain a 
prescription drug (11) 
i. Sleep-wake dimension score 
(ns) 
ii. Relaxed-tense dimension score 
(tense score b>a, p=.041; all other 
comparisons, ns)  
N/A 
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Geers, 
Weiland, et 
al. (2005) 
e 
RCT 
(B) 
Healthy student 
(57, U/K, 35.1) 
Sham 
caffeine 
pill 
a. Told they were given caffeine (U/K) 
b. No mention of caffeine (U/K) 
i. Number of caffeine symptoms 
reported (a>b, p =.03) 
Arousal suggestion x 
Cooperation prime                     
i. Higher in condition a than 
b when primed for 
cooperation (p=.02), when 
not primed for cooperation 
there is no significant 
difference between condition 
a+b 
No significant interaction 
with caffeine consumption        
Goldman et 
al. (1965) 
e 
Non 
RCT 
(B) 
Male veterans 
with 
Schizophrenia 
(64, 44.0, 100.0) 
Sham 
arousal 
treatment  
a. Told it would heighten their ward activity 
(32) 
b. Told it would lower their ward activity 
(32) 
i. Reported symptoms identified 
through interviews (U/K) 
ii. Reported drug effect identified 
through interviews (b>a, p<.001) 
ii. Ward activity (ns) 
Not assessed 
Higuchi et 
al. (2002) 
e 
RCT 
(B) 
Healthy 
volunteers 
(30, 21.2, 40.0) 
Fragrance 
(Lavender 
or 
Jasmine) 
a. Told it was relaxing (10)  
b. Told it was stimulating (10) 
c. No information given (10) 
i. Relaxed scores (ns) 
ii. Stimulant scores (Lavender, ns; 
Jasmine, c>a, p<.05; other 
comparisons U/K) 
iii. Stress reduced scores 
(Lavender, a>c, p<.05, a vs b, ns, 
b vs c, U/K; Jasmine, ns) 
N/A 
Kuenzel et 
al. (2012) 
e 
RCT 
(B) 
English 
speaking 
students 
(148, 21.7, 18.2) 
Herbal 
infusion 
tea 
a. Told it would make them feel relaxed (45) 
b. Told it would make them feel active (53) 
c. No information given (50) 
i. Symptom ratings (ns) N/A 
Lotshaw et 
al. (1996) 
e 
RCT 
(B) 
Male student 
coffee drinkers 
(50, U/K, 100.0) 
Sham 
coffee 
a. Told coffee received decaffeinated (25) 
b. Told decaffeinated received decaffeinated 
(25) 
i. Profile of mood states score (ns)    
ii. Effects of coffee received score 
(a>b, "subjects who were told 
they were receiving caffeine rated 
the effects to be significantly 
greater than subjects who were 
told they were receiving 
decaffeinated") 
N/A 
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Mikalsen et 
al. (2001)  
e 
RCT 
(W) 
Student coffee 
drinkers 
(21, 25.9, 66.7) 
Sham 
coffee 
a. Told it was caffeine 
b. Told it was not caffeine  
i. Alertness VAS score (ns) 
ii. Contentedness VAS score (ns) 
iii. Calmness VAS score (a<b, 
p<.05) 
Not assessed 
Mrna and 
Skrivanek 
(1985)  
a,b,e 
W Healthy 
volunteers 
(21, 17.0, 47.6) 
Sham 
arousal 
drug 
a. Told it was a new doping drug 
undetectable by anti-doping tests 
b. Told it was to relax pre-restart states  
i. Observed behaviour ("after the 
doping drug students were  lively 
and talkative whereas after the 
sedative they sat quietly and some 
fell asleep") 
Not assessed 
Penick and 
Fisher 
(1965)  
a,b,c,e 
W Healthy medical 
students                 
(14, U/K, U/K) 
Sham 
arousal 
drug  
a. Told they would receive a stimulant drug 
b. Told they would receive a sedative drug  
i. Overall arousal score (ns) N/A 
Schneider et 
al. (2006)  
c,e 
RCT 
(B) 
Healthy Adults 
(45, 31.0, 22.2) 
Sham 
coffee 
a. Told they were to consume decaffeinated 
coffee (15) 
b. Told they were to consume regular coffee 
(15). 
c. Informed they would receive no beverage 
and no instructions (15) 
i. Mood (ns)                                       
ii. Alertness (b>c, p=.04; all other 
comparisons, ns) 
iii. Calmness (ns) 
N/A 
Slanska et 
al. (1974)  
a,e 
 
 
  
Non 
RCT 
(B) 
Medical 
students 
(33, U/K, U/K) 
Salt 
solution 
a. Told it was a stimulant (17) 
b. Told it was a sedative (16)  
i. Perceived effect ("stimulation 
suggestion was effective in 12% 
of placebo reactors, sedation 
suggestion was effective in 25%") 
LL9LJLODQFH³6HGDWLYH
suggestion decreased alertness") 
iii. Fatigue ("b>a, statistically 
significant increase in fatigue") 
iv. Tension 
v. Relaxation                                     
Not assessed 
Walach and 
Schneider 
(2009)- Exp 
2           
RCT 
(B) 
Healthy adults 
coffee drinkers 
(30, 29.9, 33.3) 
Sham 
coffee 
a. Told it was caffeine (15) 
b. Received no beverage (15) 
i. Mean change in mood (ns) 
ii. Mean change in calmness (ns) 
iii. Mean change in alertness 
(a>b, d=0.64) 
Not assessed 
Note: RCT = Randomised Controlled Trial, Non RCT = Non randomised controlled trial, B = Between subjects design, W = Within subjects design, U/K= Unknown, ns = 
non-significant, italicised = not directly given but has been extrapolated from the available data, a = high risk random sequence generation bias, b = high risk allocation 
concealment bias c = high risk blinding of participants and personnel bias, e = did not mention an a priori sample size calculation, Not assessed = did not assess interactions 
with another risk factor, N/A = no other risk factors assessed 
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Supplementary Table 10. The effect of verbal suggestions of symptoms on symptom reporting in response to an inert exposure 
Reference 
and quality 
Study 
design 
Population 
(N, Mean age, 
%Male) 
Inert 
exposure 
Experimental conditions (n) Main effect on symptoms measured  Interaction(s) with 
other risk factors 
Bayer et al. 
(1991) 
e 
RCT 
(B) 
Unemployed Men 
(100, U/K, 100.0) 
Sham 
electrical 
shock 
a. Told they would receive a safe but 
often painful undetectable current (60) 
b. Were assured there would be no 
shocks (40) 
i. Mean pain rating (a>b, p<.01) 
ii. Frequency of pain reports (a>b, p<.05) 
No significant 
interactions with dose 
Benedetti et 
al. (1997) 
e 
RCT 
(B) 
Video assisted 
thoracoscopy 
patients 
(36, 53.7, 66.1) 
Sham 
treatment  
a. Open injection that it would increase 
pain (18) 
b. Hidden injection (18) 
i. Pain intensity rating (a>b, p<.005) N/A 
Colagiuri et 
al. (2012) 
e 
RCT 
(B) 
Students 
experiencing 
sleep difficulty      
(82, 20.2, 22.0) 
Sham 
sleeping 
pill  
a. Treatment might cause one side 
effect (29) 
b. Treatment might cause four side 
effects (23) 
c. No warning about side effects (30) 
i. Free side effect report (ns) 
ii. Change in appetite report (ns) 
iii. Severity of change in appetite (ns) 
iv. Cued report side effect (c>a+b, 
restlessness p=.04, poor concentration, 
p=.001; a vs b, ns) 
v. Severity of cued side effects ("trend" for 
c>a+b; a vs b, ns) 
N/A 
Crichton et 
al. (2014) 
e 
RCT 
(B) 
Students 
(54, U/K, 37.0) 
Sham 
infrasound 
a. TV footage detailing symptomatic 
experiences attributed to wind farms 
(27) 
b. TV footage with experts stating wind 
farms would not cause symptoms (27) 
i. Total symptom change score (a>b, p<.01) 
ii. Total symptom change severity score 
(a>b, p<.001) 
N/A 
Dalton 
(1999) 
e 
RCT 
(B) 
Healthy 
volunteers 
(180, 31.7, 49.4) 
Odours a. Told they would have relaxing 
effects (60) 
b. Told they were industrial solvents 
(60) 
c. Told they were approved for 
olfactory research (60) 
i. Symptom reports (b>a+c, p<.05) Symptom suggestions 
x Odour 
L³+LJKHVWIRUWKRVH
exposed to butanol 
following negative 
suggestions, lowest 
for those exposed to 
methyl salicylate 
following positive 
VXJJHVWLRQV´ 
No other interactions 
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assessed 
Devriese et 
al. (2004) 
a,e 
Non 
RCT 
(B+W) 
Healthy students 
(53, U/K, U/K) 
Odours a. Given information about possible 
health damaging effects of chemical 
pollution (U/K) 
b. No information (U/K) 
i. Total symptom score (ns) 
ii. Arousal symptom score (ns) 
iii. Respiratory symptom score  (ns) 
iv. Cardiac symptom score (ns) 
v. Tingling symptom score (ns) 
vi. Unclassified symptom score (ns) 
vii. Dummy symptom score (ns) 
Non assessed 
Devriese et 
al. (2006) 
RCT 
(B+W) 
Psychology 
students 
(40, U/K, 0.0) 
Odour a. Given information about possible 
health damaging effects of chemical 
pollution (20) 
b. No information (20) 
 
i. Total symptom score (ns) 
ii. Arousal symptom score (ns) 
iii. Respiratory symptom score (ns) 
iv. Cardiac symptom score (ns) 
v. Tingling symptom score (ns) 
vi. Unclassified symptom score (ns) 
vii. Dummy symptom score (ns) 
Non assessed 
Gavrylyuk et 
al. (2010) 
e 
RCT 
(B) 
Healthy 
volunteers 
(30, 24.9, 32.0) 
Saline eye 
drops 
a. Informed of pupil dilation effects 
(10) 
b. Informed of pupil constriction 
effects (10) 
c. Informed of saline eye drops (10) 
i. Frequency of symptoms (a+b>c, 
"Subjective symptoms, were more 
frequently reported by participants in the  
experimental placebo groups than by 
controls"; a vs b, ns) 
N/A 
Gibbons et 
al. (1979)  
a,e 
RCT 
(B)  
Female students 
(38, U/K, 0.0) 
Sham drug  a. Told they were taking Cavanol 
which would produce some noticeable 
side effects (19) 
b. Told they were taking baking soda 
(19)                                               
i. Perceived arousal (ns) 
ii. Salient Symptom score (a>b, p<.001) 
iii. Non salient symptom score (a>b, p<.01)     
Symptom suggestion 
x Self-awareness 
i. ns 
ii. Condition a 
reported less 
symptoms than 
condition b when 
mirror was facing 
them, (p<.03) 
iii. ns 
Heatherton 
et al. (1989)  
e 
RCT 
(B)  
Female students 
(59, U/K, 0.0) 
Sham 
vitamin 
pill  
a. Told vitamin has been reported to 
make people feel hungry (19) 
b. Told vitamin has been reported to 
make people feel full (20)                          
c. Told no further information (20) 
i. Hunger ratings (ns) No significant 
interactions with 
participant restraint 
SYSTEMATIC REVIEW OF NOCEBO EFFECT RISK FACTORS 
 
 
84 
 
Jaen and 
Dalton 
(2014)  
a,b,e 
Non 
RCT 
(B) 
Asthmatics 
(17, 38.5, 52.9) 
Sham 
active 
odour 
a. Labelled the odour as therapeutic (9) 
b. Labelled the odour as asthmogenic 
(8) 
i. Asthma symptom checklist (ns) N/A 
Neukirch 
and 
Colagiuri 
(2014)  
a,e 
RCT 
(B)  
Students with 
sleep difficulty 
(91, 21.3, 33.0) 
  
Sham sleep 
medication 
a. Warned about an increase/decrease 
in appetite and received placebo 
treatment (24) 
b. Warned about the side effect but 
received no treatment (23) 
c. Not warned about the side effects 
and received placebo treatment  (22) 
d. Not warned about the side effects 
and received no treatment (22) 
i. Free reporting of side effects (ns) 
ii. Change in appetite (ns) 
iii. Change in appetite consistent with 
warning (a, p=.008) 
iv. Severity of changes in appetite (lower for 
those warned about a decrease compared to 
those warned of an increase, p=.02, or those 
not warned, p=.012) 
v. c vs d (change in appetite, ns; direction of 
change, ns; severity of change, ns) 
N/A 
Pennebaker 
and Skelton 
(1981) 
e 
RCT 
(B) 
Students 
(38, U/K, 31.6) 
Ultrasonic 
noise 
a. Told it would increase skin 
temperature (13) 
b. Told it would decrease skin 
temperature (12) 
c. Told it would have no effect on skin 
temperature (13) 
i. Perceptions of skin temperature (a>b, 
p<.001; a>c, p<.05; b vs c, ns) 
N/A 
Put et al. 
(2004) 
a,b,c,e 
W Asthma patients 
(32, 40.0, 50.0) 
Sham 
inhaler 
a. Told it would have no effect on 
breathing 
b. Told it was a bronchoconstrictor 
c. Told it was a bronchodilator 
i. Obstruction (b>c, p<.01; a vs b, a vs c, ns) 
ii. Dyspnea (b>c, p<.01; a vs b, a vs c, ns) 
iii. Fatigue (ns) 
iv. Hyperventilation (ns) 
v. Anxiety (ns) 
vi. Irritation (ns) 
Symptom suggestion 
x Negative affect  
i+ii. Higher after 
condition b than c for 
participants with high 
negative affect (i, 
p<.01; ii, p<.05) 
iii-vi. ns 
No significant 
interactions with 
social desirability 
Read and 
Bohr (2014) 
a,b,c,e 
Non 
RCT 
(B) 
Volunteers 
without 
photosensitive 
epilepsy 
(177, 25.3, U/K) 
Sham 3D 
TV 
a. Told it was 3D and wore passive 3D 
glasses (22) 
b. Told it was 3D and wore active no 
shuttering 3D glasses (33) 
c. Told it was 2D and did not wear 
glasses (122) 
i. Symptom checklist score  (a+b>c, p=.03; a 
vs b, ns) 
Not assessed 
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Schweiger 
and Parducci 
(1981) 
e 
RCT 
B) 
Students 
(34, U/K, 52.9) 
Sham 
electric 
current 
a. Told a low current would be 
delivered, too mild to be felt but had 
produced mild headaches in the past 
(17) 
b. Told current would be too weak to 
be felt, but some people develop mild 
headaches as a side effect (17) 
i. Headache pain rating (ns) N/A 
Walach et al. 
(2002)  
RCT 
(B) 
Coffee drinkers 
(159, 25.5, 58.0) 
Sham 
coffee 
a. Received an information leaflet 
describing the pharmacological effects 
of caffeine (U/K) 
b. Received no further information 
(U/K) 
i. General wellbeing score (ns) No significant 
interaction with 
likelihood suggestion 
Winters et al. 
(2003) 
e 
Non 
RCT 
(B+W) 
18-30 year olds 
(32, U/K,15.6) 
Odour a. Given leaflet describing widespread 
chemical pollution of the environment 
is a potential cause of multiple 
chemical sensitivity (16) 
b. No information given (16) 
 
i. Total symptom score (ns) 
ii. Arousal symptom score (ns) 
iii. Respiratory symptom score (ns) 
iv. Cardiac symptom score (ns) 
v. Tingling symptom score (ns) 
vi. Unclassified symptom score (ns) 
vii. Dummy symptom score (ns) 
Symptom suggestions 
x Conditioning 
i+iii+iv+vi. Higher 
following odour 
which was paired 
with CO2 when given 
symptom suggestions 
(i, p<.01; iii+iv+vi, 
p<.05) 
ii+v+vii. ns 
No other interactions 
assessed 
Wise et al. 
(2009) 
c 
RCT 
(B) 
Patients with poor 
asthma control 
(241, 39.0, 29.5) 
Sham 
asthma 
drug 
a. Emphasized benefit of treatment and 
described potential side effects (121) 
b. Expressed uncertainty about 
improvement following treatment and 
did not describe potential side effects 
(120)  
i. Headaches (a>b, p=.03) 
ii. Lethargy (ns) 
iii. Gastrointestinal distress (ns) 
iv. Fever (ns) 
v. Rhinitis (ns) 
vi. Cough (ns) 
vii. Flu (ns) 
viii. Skin rash (ns) 
N/A 
Witthöft and 
Rubin (2013) 
RCT 
(B) 
Adult English 
speakers 
(147, 29.8, 32.7) 
Sham EMF a. Watched a documentary concerning 
the potential adverse health effects of 
Wi-Fi (76) 
b. Watched a BBC News report 
concerning the security of the internet 
i. Total symptom score (ns) 
ii. Anxiety (ns) 
iii. Head and concentration (ns) 
iv. Tingling sensations (ns) 
Symptom suggestion 
x Anxiety 
i+iii. Increased in 
people with high 
anxiety who were in 
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and mobile phone data (71) condition a (i, p=.008; 
iii, p<.001) 
ii+iv. ns 
No significant 
interactions with age, 
gender, level of 
education or 
personality  
Zimmerman
n-Viehoff et 
al. (2013)  
b,e 
RCT 
(B) 
Health 
Caucasians    
(92, 24.5, 41.3) 
Sham 
arousal 
oral spray 
a. Told it contained a drug to increase 
BP (33) 
b. Told it contained a drug to decrease 
BP (29) 
c. Told it was a placebo (30) 
i. Perceived drug effect (a>c, p=.04; b>c, 
p=.003; a vs b, ns)  
N/A 
Note: RCT = Randomised Controlled Trial, Non RCT = Non randomised controlled trial, B = Between subjects design, W = Within subjects design, U/K= Unknown, ns = 
non-significant, italicised = not directly given but has been extrapolated from the available data, a = high risk random sequence generation bias, b = high risk allocation 
concealment bias, c = high risk blinding of participants and personnel bias, e = did not mention an a priori sample size calculation, N/A = no other risk factors assessed 
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Supplementary Table 11. Miscellaneous risk factors for symptom reporting in response to an inert exposure 
Reference 
and quality 
Study 
design 
Population 
(N, Mean age, 
%Male) 
Inert 
exposure 
Manipulation Experimental conditions (n) Main effect on symptoms 
measured  
Interaction(s) with other 
risk factors 
Faasse et 
al. (2013) 
b,c,e 
RCT 
(B) 
Healthy students 
(60, 19.4, 43.5) 
Sham 
anti-
anxiety 
tablet 
Verbal 
suggestion 
(Brand) 
a. Branded reformulation change (20) 
b. Generic reformulation change (20) 
c. No change (20) 
i. Number of expected 
symptoms (b>c, p=.03; a vs 
b, ns; a vs c, ns) 
ii. Number of unexpected 
symptoms (ns) 
N/A 
Geers, 
Weiland, et 
al. (2005) 
e  
RCT 
(B) 
Healthy students 
(57, U/K, 35.1) 
Sham 
caffeine 
pill 
Cooperation 
prime 
a. Given a scrambled sentence test 
with a cooperation prime (U/K) 
b. Given a scrambled sentence test 
with a neutral prime (U/K)  
i. Caffeine symptom 
questionnaire score (ns) 
Cooperation prime x 
Arousal suggestion 
i. Higher in condition a 
than b when told they were 
given coffee (p=.02)  
No significant interactions 
with caffeine consumption     
Jensen and 
Karoly 
(1991) 
e 
RCT 
(B+W)      
Students 
(86, U/K, 45.3) 
Sham 
sedative 
pill 
Verbal 
suggestion 
(social 
desirability)  
a. Type B personality is more 
positive then type A. Type B have 
been shown to respond more to pills 
(43) 
b. Relationship between type A and B 
personality and response to pills is 
very weak (43)                                        
i. General placebo response 
rating (a>b, p<.05) 
ii. Adjective symptom 
checklist score (a>b, p<.05) 
No significant interactions 
with dose or gender 
Walach et 
al. (2001)  
 
RCT 
(B) 
Coffee drinkers 
(157, 28.1, 34.0) 
Sham 
coffee 
Experimenter 
expectancy 
a. Experimenter told the 
physiological effects from a caffeine 
placebo are real (proplacebo) (U/K) 
b. Experimenter told the effects of 
caffeine placebos are just due to 
artefacts (antiplacebo) (U/K) 
i. General wellbeing score 
(ns) 
No significant interactions 
with likelihood suggestion 
Van Diest 
et al. 
(2006) 
e 
RCT 
(B+W) 
Students 
(28, U/K, 21.4) 
Odours Type of 
breathing 
a. Test odours given with 
normocapnic breathing trial (U/K) 
b. Test odours given with 
spontaneous breathing (U/K) 
i. Paresthesia (ns) 
ii. Cerebral (ns) 
iii. Cardiac (ns) 
iv. Gastrointestinal (ns) 
v. Respiratory (a>b, no 
statistics given) 
vi. Anxiety (ns) 
Not assessed 
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vii. Neuropsychological (ns) 
viii. Unclassified (ns) 
ix. Dummy (ns) 
x. Feeling unreal (ns) 
Devriese et 
al. (2000) 
a,e 
Non 
RCT 
(B+W) 
Healthy students 
(56, U/K, 41.1) 
Odours Timing  a. Test phase immediately after 
conditioning trials (28) 
b. Test phase one week after 
conditioning trials (28) 
 
i. Total symptom score (ns) 
ii. Arousal (a>b, no statistics 
given) 
iii. Respiratory (ns) 
iv. Cardiac (ns) 
v. Tingling (ns) 
vi. Unclassified (ns) 
vii. Dummy (ns) 
Not assessed 
Note: RCT = Randomised Controlled Trial, B = Between subjects design, W = Within subjects design, U/K= Unknown, ns = non-significant, italicised = not directly given 
but has been extrapolated from the available data, a = high risk random sequence generation bias, b = high risk allocation concealment bias c = high risk blinding of 
participants and personnel bias, e = did not mention an a priori sample size calculation, Not assessed = did not assess interactions with another risk factor, N/A = no other risk 
factors assessed  
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Supplementary Table 12. Demographic predictors of symptom reporting to an inert exposure 
Reference 
and quality 
Study 
design 
Population 
(N, Mean age, %Male) 
Inert exposure Risk factor(s) Symptoms measured  Interaction(s) with other risk 
factors 
Angelucci 
and Pena 
(1997) 
e 
RCT 
(B) 
Student caffeine 
consumers 
(148, U/K, 23.0)     
Sham Coffee 1. Gender (F,M) I. Stimulation/alertness (ns) 
ii. Anxiety/irritability (ns) 
iii. Subjective symptoms (ns) 
Not assessed 
Casper et al. 
(2001) 
e 
P Nonpsychotic major 
depressive patients 
(876, U/K, 42.8) 
Sham 
fluoxetine 
treatment  
1. Gender (F,M) i. Number of people reporting one or more 
symptoms (F>M, p<.01) 
ii. Specific symptoms (F reported a higher 
incidence of pain in general, chest pain, 
infections, accidental injuries, nausea, 
increased appetite, and nervousness, ps<.043. 
M were more likely to report somnolence, 
tremor, and asthma, ps<.048) 
Not assessed 
de la Cruz et 
al. (2010) 
e 
P Patients with cancer 
related fatigue 
(105, U/K, 40.0) 
Sham 
treatment 
1. Age 
2. Education level 
i. Nausea (1 ns; higher 2 increases i, p=.05) Not assessed 
Drici et al. 
(1995) 
b,e 
P Healthy volunteers 
(52, 23.5, 50.0) 
Sham 
paracetamol 
eye drop  
1. Employment i. Subjective side effect rating scale (ns) Not assessed 
Geers et al. 
(2011) 
e 
RCT 
(B) 
Healthy students 
(102, 20.5, 21.6) 
Sham caffeine 
capsule 
1. Age 
2. Gender 
i. Placebo response index- anxious, sluggish, 
energized, calm, irritated, lazy, relaxed, and 
excited (1 ns; 2 ns)            
No significant interactions 
with likelihood suggestion 
Geers, 
Helfer, et al. 
(2005) 
e 
RCT 
(B)  
Healthy  students 
(54, 21.0, 29.6)  
Sham over-
the-counter 
pill 
1. Age 
2. Gender 
i. Affect questionnaire - Anxiety, restlessness, 
relaxed, irritable, and perspiration (1 ns; 2 ns) 
No significant interactions 
with self-awareness, 
likelihood suggestion or 
optimism  
Goetz et al. 
(2008) 
e 
P Parkinson's patients 
with dyskinesia 
(484, U/K, U/K) 
Sham 
medication 
1. Age 
2. Gender 
i. UPDRS score worsening (1 ns; 2 ns) Not assessed 
Harrell and 
Juliano 
(2012) 
e 
RCT 
(B)  
Adult smokers 
(43, 28.7, 67.4) 
Sham cigarette 1. Gender i. Cigarette evaluation scale - cravings (ns) No significant interaction 
with performance suggestion    
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Jensen and 
Karoly 
(1991) 
e 
RCT 
(B+W)     
Students 
(86, U/K, 45.3) 
Sham sedative 
pill 
1. Gender i. General placebo response rating (ns) 
ii. Adjective symptom checklist score (ns) 
No significant interaction 
with dose or social 
desirability                 
Liccardi et 
al. (2004) 
b,e 
P Patients with ADRs 
(600, 42.0, 30.3) 
Sham allergen 
pill  
1. Gender i. Number of people reporting reactions (F>M, 
p=.01) 
Not assessed 
Lombardi et 
al. (2008) 
a,d,e 
P Patients with ADRs 
(435, 39.7, 32.0) 
Sham allergen 
pill  
1. Age 
2. Gender 
i. Number of recorded symptoms (1 ns; 2 ns) Not assessed 
Lorber et al. 
(2007)  
e 
RCT 
(B) 
Students without upper 
respiratory conditions 
(86, U/K, 40.7) 
Sham 
environmental 
toxin  
1. Gender i. Verbal symptom ratings: specified- 
headache, nausea, itchy skin, drowsiness and 
additional - watery eyes, scratchy throat, chest 
tightness, and breathing difficulty (ns) 
Gender x Observation 
i. Higher in observation 
compared to no observation 
conditions when participants 
are female (p<.05) 
Mazzoni et 
al. (2010) 
e 
RCT 
(B) 
Healthy students 
(120, 20.7, 50.0) 
Sham 
environmental 
toxin  
1. Gender i. Verbal symptom ratings: specified- 
headache, nausea, itchy skin, drowsiness and 
additional - watery eyes, scratchy throat, chest 
tightness, and breathing difficulty (ns) 
Not assessed 
Papoiu et al. 
(2011) 
e 
RCT 
(W)    
Healthy volunteers and 
patients with atopic 
dermatitis 
(25, U/K, 44.0) 
Sham 
histamine  
1. Gender i. Average itch intensity rating (ns)   
ii. Scratching behaviour (ns) 
No significant interactions 
with social observation 
Read and 
Bohr (2014) 
e 
Non 
RCT 
(B) 
Volunteers without 
photosensitive epilepsy 
(177, 25.3, U/K) 
Sham 3D TV 1. Gender i. Symptom checklist score (ns) Not assessed 
Strohle 
(2000) 
e 
P Healthy adults and 
patients with panic 
disorder 
(U/K, 33.5, 56.6) 
Sham panic 
disorder 
trigger  
1. Gender i. Acute panic inventory rating scale (Healthy 
adults, ns; patients F>M, p<.05) 
Gender x Condition 
i. Increases for females with 
panic disorder (p<.05) 
Szemerszky 
et al. (2010) 
e 
W Healthy students 
(40, 22.8, 27.5) 
Sham EMF 1. Gender i. Overall symptom score (weak suggestion, 
F>M, p<.05; strong suggestion, ns) 
Not assessed 
Van den 
Bergh et al. 
(1997) 
a,e 
Non 
RCT  
(B+W) 
Psychosomatic patients  
(28, 36.0, 50.0) 
Odours 1. Gender i. Total symptom score (ns) 
ii. Arousal (ns) 
iii. Respiratory (ns) 
iv. Cardiac (ns) 
Not assessed 
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v. Tingling (ns) 
vi. Unclassified (ns) 
vii. Dummy (ns) 
Van den 
Bergh et al. 
(1998) 
e 
RCT  
(B+W) 
Healthy adults 
(56, 42.5, 50.0) 
Odours 1. Gender i. Total symptom score (ns) 
ii. Arousal (ns) 
iii. Respiratory (ns) 
iv. Cardiac (ns) 
v. Tingling (ns) 
vi. Unclassified (ns) 
vii. Dummy (ns) 
Not assessed 
Witthöft and 
Rubin 
(2013) 
RCT 
(B) 
Adult English speakers 
(147, 29.8, 32.7) 
Sham EMF 1. Age 
2. Gender 
3. Level of education 
i. Total symptom score (1 ns; 2 ns; 3 ns) 
ii. Anxiety (1 ns; 2 ns; 3 ns) 
iii. Head and concentration (1 ns; 2 ns; 3 ns) 
iv. Tingling sensations (1 ns; 2 ns; 3 ns) 
No significant interactions 
with personality, anxiety or 
symptom suggestion 
Note: RCT = Randomised Controlled Trial, Non RCT = Non randomised controlled trial, P = Prospective design, B = Between subjects design, W = Within subjects design, 
U/K= Unknown, italicised = not directly given but has been extrapolated from the available data, F = Female, M = Male, ns = non-significant, Not assessed = did not assess 
interactions with another risk factor, a = high risk for selection bias, b = high risk for confounding factors, d = high risk for low generalizability, e = did not mention an a 
priori sample size calculation 
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Supplementary Table 13. Clinical characteristics as predictors of symptom reporting to an inert exposure 
Reference and 
quality 
Study 
design 
Population 
(N, Mean age, %Male) 
Inert 
exposure 
Risk factor(s) Symptoms measured  Interaction(s) with 
other risk factors 
Andre-Obadia 
et al. (2011) 
e 
RCT 
(W) 
Chronic neuropathic pain 
patients 
(45, 55.0, 37.8)                    
Sham 
rTMS 
1. Pain ratings i. Pain rating (ns) No significant 
interaction with 
prior experience 
Bogaerts et al. 
(2010) 
e 
P Patients with medically 
unexplained dyspnea and 
healthy controls 
(58, U/K, 0.0) 
Breathing 
trial with 
room air 
1. Clinical condition i. Dyspnea score (patients reported higher scores 
than controls, p<.05) 
Not assessed 
Casper et al. 
(2001) 
e 
P Nonpsychotic major 
depressive patients 
(876, U/K, 42.8) 
Sham 
fluoxetine 
treatment  
1. Depression severity i. Number of people reporting one or more 
symptoms (ns)  
Not assessed 
Danker-Hopfe 
et al. (2010) 
P German villages with 
weak RF-EMF sources 
(397, U/K, 49.1) 
Sham EMF 1. Sleep quality i. Subjective sleep quality (lower 1 decreased i, 
p<.001) 
Not assessed 
de la Cruz et 
al. (2010) 
e 
P Patients with cancer 
related fatigue 
(105, U/K, 40.0) 
Sham 
treatment 
1. Cancer performance status 
2. Well being 
3. Cognitive status 
4. Nausea 
5. Sleep quality 
6. Anxiety symptoms 
i. Dizziness (worse 1 increased i, p=.03) 
ii. Insomnia (lower 2 increased ii, p=.01; higher 
3 increased ii, p=.01; higher 4 increased ii, 
p=.04; lower 5 increased ii, p=.04) 
iii. Nausea (higher 4 increased iii, p=.004) 
iv. Restlessness (higher 6 increased iv, p=.002) 
Not assessed 
De Peuter et 
al. (2005) 
e 
RCT 
(W) 
Asthma patients and 
healthy controls 
(40, 23.9, 52.5) 
Sham 
inhaler 
1. Clinical condition i. Total symptom score (ns) 
ii. Obstruction (ns) 
iii. Dyspnea (ns) 
iv. Fatigue (ns) 
v. Hyperventilation (Asthma patients scored 
higher than healthy controls, p<.05) 
vi. Anxiety (ns) 
vii. Irritation (ns) 
No significant 
interaction with 
association.  
No other 
interactions 
assessed. 
Flaten et al. 
(2003) 
e 
W Coffee drinkers 
(20, U/K, 50.0) 
Sham 
coffee 
1. Symptoms i. Alertness (ns) 
ii. Contentedness (ns) 
iii. Calmness (for 1 cup r=-.69, p<.01; for 2 
cups r=-.71, p<.01) 
iv. Arousal (for 1 cup r=-.76, p<.01; for 2 cups 
r=-.6, p<.01) 
Not assessed 
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v. Stress (for 1 cup r=-.67, p<.005; for 2 cups, 
ns) 
Goetz et al. 
(2008) 
e 
P Parkinson's patients with 
dyskinesia 
(484, U/K, U/K) 
Sham 
medication 
1. Dyskinesia severity 
2. UPDRS motor score 
3. Daily L-dopa dose 
4. Dyskinesia duration 
5. Adverse events 
6. Adverse event severity 
i. UPDRS score worsening (lower 1 increased i, 
p <.0001; 2 ns; 3 ns; 4 ns; 5 ns and 6 ns) 
Not assessed 
Lombardi et 
al. (2008) 
a,d,e 
P Patients with ADRs 
(435, 39.7, 32.0) 
Sham 
allergen 
pill  
1. Atopic status 
2. Previous reaction severity 
3. Type of previous reaction 
i. Recorded symptoms (1 ns; 2 ns; 3 ns) Not assessed 
Mrna and 
Skrivanek 
(1985) 
e 
W Healthy volunteers 
(21, 17.0, 47.6) 
Sham 
arousal 
drug 
1. Response to other placebo i. Drug effect questionnaire score (K =.67) Not assessed 
Nevelsteen et 
al. (2007) 
e 
RCT 
(B)  
Healthy males 
(59, 48.4, 100.0) 
Sham 
magnetic 
field 
1. Depression i. Subjective vigilance feelings (ns) 
ii. Profile of mood states (ns) 
iii. 24 Physical symptoms scale (ns) 
Not assessed 
Papoiu et al. 
(2011) 
e 
RCT 
(W)    
Healthy volunteers and 
patients with atopic 
dermatitis 
(25, U/K, 44.0) 
Sham 
histamine  
1. Clinical condition i. Average itch intensity rating (higher in itch 
video compared to neutral video for patients, 
p=.027; healthy volunteers, ns)                        
ii. Itching behaviour (patients scratched more 
frequently in areas beyond the itch site, p=.001, 
compared to healthy volunteers when watching 
the itch video) 
Not assessed 
Strohle (2000) 
e 
P Healthy adults and 
patients with panic 
disorder 
(U/K, 33.5, 56.6) 
Sham 
panic 
disorder 
trigger  
1. Clinical condition i. Acute panic inventory rating scale (patients 
scored higher than healthy volunteers, p<.05) 
Condition x Gender 
i. Increased in 
Females with panic 
disorder (p<.05) 
Szemerszky et 
al. (2010) 
e 
W Healthy students 
(40, 22.8, 27.5) 
Sham EMF 1. IEI EMF score i. Overall symptom score (for weak suggestion 
r=.46, p<.01; for strong suggestion; r=.48, 
p<.01; regression, ns) 
Not assessed 
Note: RCT = Randomised Controlled Trial, P = Prospective design, B = Between subjects design, W = Within subjects design, U/K= Unknown, italicised = not directly given 
but has been extrapolated from the available data, UPDRS = Unified Parkinson's disease rating scale, IEI-EMF = idiopathic environmental intolerance attributed to 
electromagnetic fields, ns = non-significant, Not assessed = did not assess interactions with another risk factor, a = high risk for selection bias, d = high risk for low 
generalizability, e = did not mention an a priori sample size calculation 
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Supplementary Table 14. Expectations as predictors of symptom reporting to an inert exposure 
Reference and 
quality 
Study 
design 
Population 
(N, Mean age, 
%Male) 
Inert exposure Risk factor(s) Symptoms measured  Interaction(s) 
with other risk 
factors 
Angelucci and 
Pena (1997) 
e 
RCT 
(B) 
Student caffeine 
consumers 
(148, U/K, 23.0)     
Sham coffee 1. Expectations of 
the effect of coffee 
I. Stimulation/alertness (ns) 
ii. Anxiety/irritability (ns) 
iii. Subjective symptoms (ns) 
Not assessed 
Bayer et al. 
(1998)  
a,e 
RCT 
(B) 
Job seekers 
(62, U/K, 82.0) 
Sham electrical 
shock 
1. Believed what 
they were told 
i. Subjects reporting pain (ns)                                                   Not assessed 
De Peuter et 
al. (2005) 
e 
RCT 
(W) 
Asthma patients 
and healthy controls 
(40, 23.9, 52.5) 
Sham inhaler 1. Symptom 
expectations 
i. Total symptom score (overall, r=0.52, p<.001; control, 
ns; asthma patients, r=0.69, p<.001) 
Not assessed 
Fillmore and 
Vogel-Sprott 
(1992) 
e 
P Male students 
(56, U/K, 100.0) 
Sham coffee 1. Symptom 
expectations 
i. Alertness score (higher 1increased i, p<.001) 
ii. Tension score (higher 1 increased ii, p<.001) 
N/A 
Flaten et al. 
(2003) 
e 
W Coffee drinkers 
(20, U/K, 50.0) 
Sham coffee 1. Symptom 
expectations 
i. Alertness (for 1 cup r=.63, p<.005; for 2 cups r=.76, 
p<.001) 
ii. Discontentedness (for 1 cup r=.57, p<.01; for 2 cups, ns) 
iii. Calmness (ns) 
iv. Arousal (ns) 
v. Stress  (ns) 
Not assessed 
Köteles and 
Babulka 
(2014) 
a,d,e 
P Adult volunteers 
(33, 37.7,15.2) 
3 types of Essential 
oils (Randomised to 
1) 
1. Symptom 
expectations 
i. Perceived change in alertness: rosemary oil (ns), 
lavender oil (higher 1 increased i, p<.001), eucalyptus oil 
(ns) 
ii. Perceived change in heart rate: rosemary oil (ns), 
lavender oil (ns), eucalyptus oil (ns) 
iii. Perceived change in BP: rosemary oil (ns), lavender oil 
(ns), eucalyptus oil (ns)    
Not assessed 
Link et al. 
(2006) 
a,b,c,d,e 
P Students 
(36, 22.7, 44.0) 
Sham herbal 
supplement 
1. Belief they had 
taken active 
supplement 
i. Number of symptoms reported (those who thought they 
had taken the active supplement reported more symptoms 
than those who thought they had taken the placebo, 
p=.003) 
Not assessed 
Molcan and et 
al. (1982) 
P Medical students 
(48, U/K, 52.1) 
Sham arousal pill 1. Symptom 
expectations 
i. Symptom scale score (ns) Not assessed 
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b,e 
Szemerszky et 
al. (2010) 
e 
W Healthy students 
(40, 22.8, 27.5) 
Sham EMF 1. Symptom 
expectations 
i. Overall symptom score (for weak EMF r=.49, p<.01; for 
strong EMF r=.42, p<.01; regression ns) 
Not assessed 
Vase et al. 
(2013) 
e 
P Patient with pain 
due to tooth 
removal 
(U/K, 25.5, 47.5) 
Sham acupuncture 1. Symptom 
expectations 
i. Pain intensity (higher 1 increased i, p=.001) 
ii. Pain unpleasantness (higher 1 increased ii, p<.001) 
Not assessed 
Walach et al. 
(2001) 
RCT 
(B) 
Coffee drinkers 
(157, 28.1, 34.0) 
Sham coffee 1. General 
expectations about 
coffee on wellbeing 
2. Subjective 
probability of 
receiving coffee 
i. General wellbeing score (1 ns; 2 ns) Not assessed 
Walach and 
Schneider 
(2009)- exp 1 
RCT 
(B) 
Healthy adults 
coffee drinkers 
(60, 32.3, 23.3) 
Sham caffeine 
beverage 
1. Symptom 
expectations 
i. Mean change in mood (ns) 
ii. Mean change in calmness (ns) 
iii. Mean change in alertness (ns) 
Not assessed 
Walach and 
Schneider 
(2009)- exp 2 
RCT 
(B) 
Healthy adults 
coffee drinkers 
(30, 29.9, 33.3) 
Sham caffeine 
beverage 
1. Symptom 
expectations 
i. Mean change in mood (ns) 
ii. Mean change in calmness (ns) 
iii. Mean change in alertness (ns) 
Not assessed 
Note: RCT = Randomised Controlled Trial, P = Prospective design, B = Between subjects design, W = Within subjects design, U/K= Unknown, italicised = not directly given 
but has been extrapolated from the available data, ns = non-significant, Not assessed = did not assess interactions with another risk factor, N/A = no other risk factors 
assessed, a = high risk for selection bias, b = high risk for confounding factors, c = high risk for insufficient follow-up, d = high risk for low generalizability, e = did not 
mention an a priori sample size calculation 
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Supplementary Table 15. Anxiety as a predictor of symptom reporting to an inert exposure 
Reference 
and quality 
Study 
design 
Population 
(N, Mean age, %Male) 
Inert 
exposure 
Risk factor(s) Symptoms measured  Interaction(s) with other risk factors 
Angelucci 
and Pena 
(1997) 
e 
RCT 
(B) 
Student caffeine 
consumers 
(148, U/K, 23.0)     
Sham coffee 1. State and trait 
anxiety 
I. Stimulation/alertness (ns) 
ii. Anxiety/irritability (higher 
1 increased ii, p<.0001) 
iii. Subjective symptoms (ns) 
Not assessed 
Bogaerts et 
al. (2010) 
e 
P Patients with medically 
unexplained dyspnea and 
healthy controls 
(58, U/K, 0.0) 
Breathing 
trial with 
room air 
1. State anxiety i. Dyspnea score (ns) Not assessed 
Danker-
Hopfe et al. 
(2010) 
P Villages in Germany with 
weak RF-EMF sources 
(397, U/K, 49.1) 
Sham EMF 1. General 
fear/anxiety towards 
risks of RF-EMF 
2. Fear/anxiety 
towards base station    
i. Subjective sleep quality (1 
ns; higher 2 decreased i, 
p<.05) 
Not assessed 
Link et al. 
(2006) 
a,b,c,d,e 
P Students 
(36, 22.7, 44.0) 
Sham herbal 
supplement 
1. State anxiety i. Number of symptoms 
reported (ns) 
Not assessed 
Molcan and 
et al. (1982) 
b,e 
P Medical students 
(48, U/K, 52.1) 
Sham arousal 
pill 
1. State anxiety 
2. Trait anxiety 
i. Symptom scale score (1 ns; 
2 ns) 
Not assessed 
Nevelsteen 
et al. (2007) 
e 
RCT 
(B)  
Healthy males 
(59, 48.4, 100.0) 
Sham 
magnetic 
field 
1. State anxiety 
2. Trait anxiety 
i. Subjective vigilance feelings 
(1 ns; 2 ns) 
ii. Profile of mood states (1 ns; 
2 ns) 
iii. 24 Physical symptoms 
scale (higher 1 increased iii, 
p<.001; 2 ns) 
Not assessed 
Szemerszky 
et al. (2010) 
e 
W Healthy students 
(40, 22.8, 27.5) 
Sham EMF 1. State anxiety i. Overall symptom score (ns) Not assessed 
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Van den 
Bergh et al. 
(1997) 
a,e 
Non 
RCT  
(B+W) 
Psychosomatic patients 
(28, 36.0, 50.0) 
Odours 1. State and trait 
anxiety 
i. Total symptom score (ns) 
ii. Arousal (ns) 
iii. Respiratory (ns) 
iv. Cardiac (ns) 
v. Tingling (ns) 
vi. Unclassified (ns) 
vii. Dummy (ns) 
Not assessed 
Witthöft and 
Rubin 
(2013) 
RCT 
(B) 
Adult English speakers 
(147, 29.8, 32.7) 
Sham EMF 1. State anxiety i. Total symptom score (ns) 
ii. Anxiety (ns) 
iii. Head and concentration 
(ns) 
iv. Tingling sensations (ns) 
Anxiety x Symptom suggestion 
i+iii. Increased in people with high levels 
of anxiety who were in Wi-Fi group (i, 
p=.008; iii, p<.001).                                         
ii+iv. ns 
No significant interactions with age, 
gender, level of education or personality 
Note: RCT = Randomised Controlled Trial, P = Prospective design, B = Between subjects design, W = Within subjects design, U/K= Unknown, ns = non-significant, Not 
assessed = did not assess interactions with another risk factor, a = high risk for selection bias, b = high risk for confounding factors, c = high risk for insufficient follow-up, d 
= high risk for low generalizability, e = did not mention an a priori sample size calculation 
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Supplementary Table 16. Personality as a predictor of symptom reporting to an inert exposure 
 
Reference and 
quality 
Study 
design 
Population 
(N, Mean age, 
%Male) 
Inert 
exposure 
Risk factor(s) Symptoms measured  Interaction(s) with other risk 
factors 
Angelucci and 
Pena (1997) 
e 
RCT 
(B) 
Student caffeine 
consumers 
(148, U/K, 23.0)     
Sham coffee 1. Suggestibility I. Stimulation/alertness (ns) 
ii. Anxiety/irritability (ns) 
iii. Subjective symptoms (ns) 
Not assessed 
Bogaerts et al. 
(2010) 
e 
P Patients with 
medically 
unexplained 
dyspnea and 
healthy controls 
(58, U/K, 0.0) 
Breathing 
trial with 
room air 
1. Negative affect i. Dyspnea score (ns) Not assessed 
Davis et al. 
(1995) 
a,d,e 
P Healthy Adults 
(27, U/K, 55.6) 
Sham anti-
depressant 
pill 
1. Neuroticism 
2. Somatosensory 
amplification     
L6LGHHIIHFWFKHFNOLVW³VLJQLILFDQW
SRVLWLYHFRUUHODWLRQ´QV 
Not assessed 
De Peuter et 
al. (2005) 
e 
RCT 
(W) 
Asthma patients 
and healthy controls  
(40, 23.9, 52.5) 
Sham 
inhaler 
1. Negative affect i. Total symptom score (ns) 
ii. Obstruction (ns) 
iii. Dyspnea (ns) 
iv. Fatigue (ns) 
v. Hyperventilation (ns) 
vi. Anxiety (ns) 
vii. Irritability (higher 1 increased vii, 
p<.05) 
Not assessed 
De Peuter et 
al. (2007) 
e 
P Asthma patients 
(30, 38.0, 26.7) 
Sham 
histamine 
inhalation 
1. Negative affect i. Obstruction (higher 1 increased i, p<.05) 
ii. Dyspnea (ns) 
iii. Fatigue (higher 1 increased iii, p<.001) 
iv. Hyperventilation (ns) 
v. Anxiety (ns) 
vi. Irritability (higher 1 increased vi, 
p<.001) 
None 
Devriese et al. 
(2000) 
a,e 
Non 
RCT 
(B+W) 
Healthy students 
(56, U/K, 41.1) 
Odours 1. Negative affect i. Total symptom score (ns) 
ii. Arousal (ns) 
iii. Respiratory (ns) 
iv. Cardiac (ns) 
v. Tingling (ns) 
Conditioning x Odour x Negative 
affect 
i+iii. Higher in response to odour 
paired with CO2 but only when 
the odour was ammonia and 
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vi. Unclassified (ns) 
vii. Dummy (ns) 
participants had high negative 
affect (p<.05) 
ii, iv-vii. ns 
Odour x Negative affect x 
Generalisation 
i+iii. Higher in response to butyric 
and acetic acid than citric aroma 
when ammonia was paired with 
CO2 and participants had high 
negative affect (p<.05) 
iv. Higher in response to butyric 
acid than acetic acid or citric 
aroma when ammonia was paired 
with CO2 and participants had 
high negative affect (p<.05) 
ii+ v-vii. Ns 
No other interactions assessed 
Devriese et al. 
(2004) 
a,e 
Non 
RCT 
(B+W) 
Healthy students 
(53, U/K, U/K) 
Odours 1.  Negative affect 
 
i. Total symptom score (ns) 
ii. Arousal (ns) 
iii. Respiratory (ns) 
iv. Cardiac (ns) 
v. Tingling (ns) 
vi. Unclassified (ns) 
vii. Dummy (ns) 
Non assessed 
Drici et al. 
(1995) 
b,e 
P Healthy volunteers      
(52, 23.5, 50.0) 
Sham 
paracetamol 
eye drop  
1. Type A Personality      
2. Type B Personality 
i. Subjective side effect reports (1>2, 
p=.03) 
Not assessed 
Geers, Helfer, 
et al. (2005) 
e 
RCT 
(B)  
Healthy  students 
(54, 21.0, 29.6)  
Sham over-
the-counter 
pill 
1. Optimism-
pessimism 
i. Affect questionnaire - Anxiety, 
restlessness, relaxed, irritable, and 
perspiration (ns) 
Optimism x Likelihood suggestion 
i. Increased score for pessimists 
than optimists in deceptive group 
than the control (p<.05), no 
significant difference between 
conditional group and control. 
 No significant interaction with 
age, gender or self-awareness   
Heatherton et 
al. (1989)  
RCT 
(B)  
Female students 
(59, U/K, 0.0) 
Sham 
vitamin pill  
1. Restraint i. Hunger ratings (ns) No significant interaction with 
symptom suggestion  
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e 
Link et al. 
(2006) 
a,b,c,d,e 
P Students 
(36, 22.7, 44.0) 
Sham herbal 
supplement 
1. Social desirability i. Number of symptoms reported (ns) Not assessed 
Mazzoni et al. 
(2010) 
e 
RCT 
(B) 
Healthy students 
(120, 20.7, 50.0) 
Sham 
environment
al toxin  
1. Openness 
2. Conscientiousness 
3. Extraversion                 
4. Agreeableness              
5. Neuroticism 
i. Verbal symptom reports (1 ns; 2 ns; 3 ns; 
4 ns; 5 ns) 
Not assessed 
Nevelsteen et 
al. (2007) 
e 
RCT 
(B)  
Healthy males 
(59, 48.4, 100.0) 
Sham 
magnetic 
field 
1. Positive affect 
2. Negative affect 
3. Sensitivity to anxiety 
4. Vigilance 
i. Subjective vigilance feelings (1 ns; 2 ns; 
3 ns; 4 ns) 
ii. Profile of mood states (1 ns; 2 ns; 3 ns; 
4 ns) 
iii. 24 Physical symptoms score (higher 1 
decreased ii, p<.001; 2+3 ns; higher 4 
increased iii, p<.001) 
Not assessed 
Put et al. 
(2004) 
a,b,c,e 
W Asthma patients 
(32, 40.0, 50.0) 
Sham 
inhaler 
1. Negative affect 
2. Social desirability 
i. Obstruction (higher 1 increased i, p<.01; 
2 ns) 
ii. Dyspnea (higher 1 increased ii, p<.01; 2 
ns) 
iii. Fatigue (higher 1 increased iii, p<.05; 2 
ns) 
iv. Hyperventilation (higher 1 increased iv, 
p<.05; 2 ns) 
v. Anxiety (higher 1 increased v, p<.05; 2 
ns) 
vi. Irritation (higher 1 increased vi, p<.05; 
2 ns) 
Symptom suggestion x negative 
affect  
i+ii. Higher after 
bronchoconstriction than 
bronchodilator suggestions for 
those with high negative affect (i, 
p<.01; ii, p<.05) 
iii-vi. ns 
No significant interactions with 
social desirability 
Slanska et al. 
(1974)  
a,e 
 
 
  
Non 
RCT 
(B) 
Medical students 
(33, U/K, U/K) 
Indifferent 
salt solution
  
1. Stability ± instability 
2. Activity ± passivity 
3. Submissive ± 
dominance 
4. Rationality ± 
sensuousness 
5. Introversion - 
extraversion  
i. Perceived effect ("correlated with 1+3 
personality characteristics. Whereby 
significant changes in the direction of 
suggestion mainly affecting individuals 
unstable and submissive") 
Not assessed 
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Stegen et al. 
(1998) 
e 
RCT 
(W) 
Healthy psychology 
students 
(72, U/K, 48.6) 
Breathing 
trial with 
room air 
1. Negative affect i. Total symptom score (ns) 
ii. General arousal (ns) 
iii. Respiration (ns) 
iv. Cardiac (ns) 
v. Tingling (ns) 
vi. Unclassified (ns) 
vii. Gastrointestinal (ns) 
viii. Dizziness (ns) 
Prior experience x Negative affect 
i+ii. Higher in participants scoring 
high on negative affect compared 
to low when room air trial was 
before CO2 trial (i, p<.001; ii, 
p<.005) 
iii-viii. ns 
Stegen et al. 
(2000) 
a,b,d,e 
P Healthy psychology 
students 
(44, U/K, 27.3) 
Breathing 
trial with 
room air 
1. Negative affect 
2. Social desirability 
i. Somatic experience intensity (higher 1 
increased i, p<.01; 2  ns) 
ii. Unpleasantness (1 ns; 2, ns) 
iii. General arousal (1 ns; 2 ns) 
iv. Respiration (higher 1 increased iv, 
p<.05; 2 ns) 
v. Cardiac (1 ns; 2 ns) 
vi. Tingling (higher 1 increased vi, p<.05; 
2 ns) 
vii. Gastrointestinal (1 ns; 2 ns) 
viii. Unclassified sensations (higher 1 
increased viii, p<.05; 2 ns) 
ix. Dummy sensations (1 ns; 2 ns) 
Not assessed 
Sullivan et al. 
(2008) 
e 
P Patients with 
neuropathic pain 
(24, 54.7, 62.5) 
Sham cream 
treatment 
1. Pain catastrophising i. Side effects reported (r=0.29, p<.05) N/A 
Szemerszky et 
al. (2010) 
e 
W Healthy students 
(40, 22.8, 27.5) 
Sham EMF 1. Dispositional 
optimism 
2. Somatisation 
3. Somatosensory 
amplification 
4. Motivation 
i. Overall symptom score (1+4 significant 
negative correlation; 2+3 significant 
positive correlation for weak and strong; 
regression of 2,3,4 was significant for 
weak suggestion, only 2+4 were 
significant for strong suggestion) 
Not assessed 
Van den 
Bergh et al. 
(1995) 
a,e 
Non 
RCT  
(B+W) 
Healthy students 
(28, U/K, 50.0) 
Odours 1. Negative affect 
 
i. Total symptom score (ns) 
ii. Arousal symptom score (ns) 
iii. Respiratory symptom score (ns) 
iv. Cardiac symptom score (ns) 
v. Tingling symptom score (ns) 
vi. Unclassified symptom score (ns) 
Not assessed 
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Van den 
Bergh et al. 
(1997) 
a,e 
Non 
RCT  
(B+W) 
Psychosomatic 
patients  
(28, 36.0, 50.0) 
Odours 1. Blunting behaviour 
 
i. Total symptom score (Higher 1 
increased i, p<.002) 
ii. Arousal symptom score (ns) 
iii. Respiratory symptom score (ns) 
iv. Cardiac symptom score (ns) 
v. Tingling symptom score (ns) 
vi. Unclassified symptom score (Higher 1 
increased vi, p<.005) 
vii. Dummy symptom score (ns) 
Not assessed 
Witthöft and 
Rubin (2013) 
RCT 
(B) 
Adult English 
speakers                  
(147, 29.8, 32.7) 
Sham EMF 1. Perceived sensitivity 
to EMF 
2. Modern health 
worries 
3. Somatisation 
4. Somatosensory 
amplification  
i. Total symptom score (1 ns; higher 2 
increased i, p<.001; 3 ns; higher 4 
increased i, p=.046) 
ii. Anxiety (ns) 
iii. Head and concentration (1ns; higher 2 
increased iii, p<.001; 3 ns; 4 ns) 
iv. Tingling sensations (ns) 
No significant interactions with 
age, gender, level of education, 
anxiety or symptom suggestion 
Note: RCT = Randomised Controlled Trial, Non RCT = Non randomised controlled trial, P = Prospective design, B = Between subjects design, W = Within subjects design, 
U/K= Unknown, ns = non-significant, Not assessed = did not assess interactions with another risk factor, N/A = no other risk factors assessed, a = high risk for selection bias, 
b = high risk for confounding factors, c = high risk for insufficient follow-up, d = high risk for low generalisabilty, e = did not mention an a priori sample size calculation 
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Supplementary Table 17. Miscellaneous baseline predictors of symptom reporting to an inert exposure 
Reference and 
quality 
Study 
design 
Population 
(N, Mean age, %Male) 
Inert exposure Risk factor(s) Symptoms measured  Interaction(s) with other risk factors 
Dalton (1999) 
e 
RCT 
(B) 
Healthy volunteers 
(180, 31.7, 49.4) 
Odours 1. Olfactory 
sensitivity 
2. Odour reactivity 
i. Symptom reports (1 ns;  higher 2 
increases i, R2=0.74) 
Not assessed 
Danker-Hopfe 
et al. (2010)  
P Villages in Germany 
with weak RF-EMF 
sources 
(397, U/K, 49.1) 
Sham EMF 1. Visibility of the 
base station 
2. Preoccupation 
with EMF 
i. Subjective sleep quality (1 ns; 2 
ns) 
Not assessed 
Devriese et al. 
(2004) 
a,e 
Non 
RCT 
(B+W) 
Healthy students 
(53, U/K, U/K) 
Odours 1.  Perceived cue 
odour 
 
i. Total symptom score (ns) 
ii. Arousal symptom score (ns) 
iii. Respiratory symptom score (ns) 
iv. Cardiac symptom score (ns) 
v. Tingling symptom score (ns) 
vi. Unclassified symptom score (ns) 
vii. Dummy symptom score (ns) 
Perceived cue odour x Odour 
i. Higher to butyric acid than ammonia 
when butyric acid was thought to have 
been paired with CO2 (p<.05) 
ii-vii. ns 
No other interactions assessed 
Geers et al. 
(2011) 
e 
RCT 
(B) 
Healthy students 
(102, 20.5, 21.6) 
Sham caffeine 
capsule 
1. Average 
caffeinated 
beverage 
consumption 
2. Caffeinated 
beverages 
consumed so far 
that day 
i. Placebo response index- anxious, 
sluggish, energized, calm, irritated, 
lazy, relaxed, and excited (1 ns; 2 
ns)            
 
No significant interactions with 
likelihood suggestion 
Geers, 
Weiland, et al. 
(2005)  
e 
RCT 
(B) 
Healthy students 
(57, U/K, 35.1) 
Sham caffeine 
pill 
1. Caffeine 
consumption 
i. Caffeine symptom questionnaire 
score (ns) 
No significant interaction with arousal 
suggestion 
Goetz et al. 
(2008) 
e 
P Parkinson's patients 
with dyskinesia 
(484, U/K, U/K) 
Sham 
medication 
1. Geographical site 
of enrolment 
2. Study (1 or 2) 
i. UPDRS score worsening (1 ns; 2 
ns) 
Not assessed 
Goldman et 
al. (1965) 
e 
Non 
RCT 
(B) 
Male veterans with 
Schizophrenia 
(64, 44.0, 100.0) 
Sham arousal 
treatment  
1. High regard for 
hospital 
medications 
i. Reported symptoms identified 
through interviews (U/K) 
ii. Increase in reported drug effects 
identified through interviews 
Not assessed 
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(C=.30, p<.01) 
iii. Ward activity (U/K) 
Köteles and 
Babulka 
(2014) 
a,d,e 
P Adult volunteers 
(33, 37.7, 15.2) 
3 types of 
Essential oils 
(Randomised 
to 1) 
1. Pleasantness of 
odour 
i. Perceived change in alertness: 
rosemary oil (ns), lavender oil (ns), 
eucalyptus oil (increased, p<.05) 
ii. Perceived change in heart rate: 
rosemary oil (ns), lavender oil (ns), 
eucalyptus oil (ns) 
iii. Perceived change in BP: 
rosemary oil (ns), lavender oil (ns), 
eucalyptus oil (increased, p<.05)    
Not assessed 
Liccardi et al. 
(2004) 
b,e 
P Patients with ADRs 
(600, 42.0, 30.3) 
Sham allergen 
pill  
1. Hospital centre i. Number of people reporting 
reactions (ns) 
Not assessed 
Mazzoni et al. 
(2010) 
e 
RCT 
(B) 
Healthy students 
(120, 20.7, 50.0) 
Sham 
environmental 
toxin  
1. Gender of model i. Verbal symptom ratings (more 
symptoms were reported when 
participant and confederate were 
the same gender, d=0.24) 
Not assessed 
Meulders et 
al. (2010) 
a,e 
Non 
RCT 
(B+W) 
Healthy adults 
(58, 22.0, 48.3) 
Odours 1. Ability to predict 
which odour 
produced the most 
symptoms 
i. Total symptom score (ns) 
ii. Arousal (ns) 
iii. Respiratory (ns) 
iv. Cardiac (ns) 
v. Tingling (ns) 
vi. Unclassified (ns) 
vii. Dummy (ns) 
Conditioning x Ability to predict 
i. Higher in response to odours which 
had been paired with CO2 compared to 
room air when participants were able to 
predict which odour had caused the 
most symptoms (p<.05) 
ii-vii. ns 
Conditioning x Ability to predict x 
Odour 
i-iv+vii. Higher in response to butyric 
acid which had been paired with CO2 
compared to room air when participants 
were able to predict which odour had 
caused the most symptoms (i-iv, p<.01; 
vii, p<.05) 
v+vi. ns 
No other interactions assessed 
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Nevelsteen et 
al. (2007) 
e 
RCT 
(B)  
Healthy males 
(59, 48.4, 100.0) 
Sham 
magnetic field 
1. Discomfort under 
the helmet 
2. Stress under the 
helmet 
3. Risk perception 
i. Subjective vigilance feelings (1 
ns; 2 ns; 3 ns) 
ii. Profile of mood states (1 ns; 2 
ns; 3 ns) 
iii. 24 Physical symptoms scale 
(higher 1 increased iii, p<.001; 2, 
ns; 3, ns) 
Not assessed 
Wendt et al. 
(2014) 
e 
P Healthy males 
(24, 25.0, 100.0)      
Sham 
immuno-
suppressive 
capsule 
1. Genes i. Number of symptoms reported 
(More side effects in the Val/Val 
homozygous carriers compared to 
the Val158/Met158 groups, 
p<0.001 and the Met158 
homozygous groups, p<.01)  
N/A 
Note: RCT = Randomised Controlled Trial, P = Prospective design, B = Between subjects design, U/K= Unknown, ns = non-significant, Not assessed = did not assess 
interactions with another risk factor, N/A = no other risk factors assessed, a = high risk for selection bias, b = high risk for confounding factors, d = high risk for low 
generalizability, e = did not mention an a priori sample size calculation 
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Appendix 1. Data extraction sheet 
 
Reference Study 1 Study 2 Study 3 « 
    Country of origin     
Participants     
    Age     
    Gender     
    Inclusion/exclusion    
    criteria     
    Sample size (sample  
    size calculation  
    provided?) 
    
    Number of drop outs      
Methods     
    Design     
    Materials     
        Exposure type     
        Experimental    
        condition(s)     
    Measures     
        Baseline risk  
        factor(s)     
        Symptoms      
    Statistical analysis     
        Baseline risk  
        factor(s)     
        Condition      
Results     
    Effect of condition on      
    factor(s)     
    Effect of baseline risk  
    factor(s) on symptoms     
Ethical Issues     
    Ethical approval?     
    Details of informed  
    consent     
